MeSH term
Frequency | Condition_Probility | Animals | 186 | 0.0 |
Humans | 1562 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Cell Culture Techniques | 8 | 1.0 |
Cell Differentiation/*physiology | 2 | 0.0 |
Alleles | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 813 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Antigens, CD19/*biosynthesis | 4 | 80.0 |
Cell Line | 77 | 0.0 |
Cell Membrane/metabolism | 5 | 0.0 |
Cell Separation | 42 | 3.0 |
Cell Transformation, Viral | 9 | 3.0 |
Epstein-Barr Virus Nuclear Antigens/metabolism | 2 | 18.0 |
Flow Cytometry | 326 | 5.0 |
Herpesvirus 4, Human/*metabolism | 3 | 7.0 |
Immunophenotyping | 335 | 11.0 |
Leukocytes, Mononuclear/metabolism | 9 | 4.0 |
Phenotype | 142 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 19 | 0.0 |
*Signal Transduction | 17 | 0.0 |
Time Factors | 56 | 0.0 |
Viral Matrix Proteins/metabolism | 2 | 11.0 |
Adult | 552 | 0.0 |
Antigens, CD/*analysis | 90 | 11.0 |
B-Lymphocytes/*immunology | 113 | 13.0 |
CD4-Positive T-Lymphocytes/*immunology | 9 | 1.0 |
CD8-Positive T-Lymphocytes/*immunology | 5 | 1.0 |
Cell Communication | 3 | 1.0 |
Female | 649 | 0.0 |
Immunocompetence | 4 | 9.0 |
*Enteral Nutrition | 2 | 8.0 |
Infant, Newborn | 45 | 1.0 |
Infant, Premature | 5 | 4.0 |
Milk, Human/chemistry | 2 | 13.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 29 | 0.0 |
Antigens, CD/analysis | 164 | 9.0 |
Antigens, CD14/analysis | 5 | 4.0 |
Antigens, CD19/analysis | 45 | 51.0 |
Antigens, CD3/analysis | 24 | 9.0 |
Antigens, CD4/analysis | 18 | 4.0 |
Antigens, CD45/analysis | 17 | 6.0 |
Antigens, CD8/analysis | 13 | 5.0 |
Comparative Study | 169 | 0.0 |
Fluorescent Antibody Technique | 66 | 2.0 |
In Vitro | 31 | 0.0 |
Abortion, Habitual/*immunology | 2 | 8.0 |
Cytotoxicity, Immunologic | 19 | 1.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
Killer Cells, Natural/immunology | 27 | 6.0 |
Lymphocyte Subsets/immunology | 19 | 13.0 |
Pregnancy | 27 | 0.0 |
Aged | 324 | 1.0 |
Cross-Sectional Studies | 9 | 0.0 |
Male | 674 | 0.0 |
Middle Aged | 494 | 1.0 |
Retrospective Studies | 22 | 0.0 |
Cyclophosphamide/administration & dosage | 8 | 3.0 |
Doxorubicin/administration & dosage/analogs & derivatives | 3 | 37.0 |
Drug Administration Schedule | 11 | 1.0 |
English Abstract | 143 | 1.0 |
Prednisolone/administration & dosage | 6 | 8.0 |
Remission Induction | 33 | 5.0 |
Vincristine/administration & dosage | 12 | 7.0 |
Adolescent | 226 | 1.0 |
Antigens, CD/*metabolism | 26 | 4.0 |
B-Lymphocytes/cytology/*metabolism | 6 | 25.0 |
Cell Division | 35 | 0.0 |
Cell Lineage | 25 | 6.0 |
Child | 199 | 1.0 |
Child, Preschool | 135 | 1.0 |
Infant | 93 | 1.0 |
Ligands | 11 | 0.0 |
Receptors, IgG/*metabolism | 3 | 4.0 |
Research Support, U.S. Gov't, P.H.S. | 255 | 0.0 |
CD4-CD8 Ratio | 32 | 5.0 |
Chronic Disease | 17 | 0.0 |
Flow Cytometry/*methods | 37 | 16.0 |
Immunophenotyping/*methods | 14 | 20.0 |
Lymphocyte Count | 73 | 10.0 |
Tumor Cells, Cultured | 136 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Immunohistochemistry | 60 | 0.0 |
DNA/metabolism | 3 | 0.0 |
Dose-Response Relationship, Drug | 10 | 0.0 |
Karyotyping | 63 | 3.0 |
Anti-Asthmatic Agents/*therapeutic use | 2 | 20.0 |
Asthma/drug therapy/*immunology | 2 | 25.0 |
Epitopes/analysis | 5 | 2.0 |
Immunity, Cellular/drug effects | 3 | 5.0 |
Leukocyte Count | 54 | 3.0 |
Lymphocyte Activation | 61 | 1.0 |
Cell Division/immunology | 12 | 4.0 |
Interleukin-10/pharmacology | 2 | 2.0 |
T-Lymphocyte Subsets/immunology/metabolism | 2 | 4.0 |
Cytokines/immunology | 3 | 2.0 |
Monocytes/immunology | 6 | 1.0 |
Polymerase Chain Reaction | 55 | 0.0 |
T-Lymphocyte Subsets/*immunology | 25 | 4.0 |
Prednisone/administration & dosage | 6 | 7.0 |
Skin/*pathology | 6 | 6.0 |
Tumor Markers, Biological/*analysis | 20 | 2.0 |
Tumor Stem Cells/*chemistry | 3 | 16.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 16 | 3.0 |
Developing Countries | 2 | 2.0 |
Disease-Free Survival | 7 | 0.0 |
Life Tables | 7 | 4.0 |
Neprilysin/analysis | 15 | 28.0 |
Philadelphia Chromosome | 3 | 6.0 |
Survival Analysis | 16 | 0.0 |
Survival Rate | 10 | 0.0 |
Treatment Outcome | 39 | 1.0 |
ADP-ribosyl Cyclase | 32 | 7.0 |
*Antigens, CD | 32 | 4.0 |
Antigens, Differentiation/biosynthesis | 7 | 13.0 |
B-Lymphocytes/*metabolism | 14 | 7.0 |
Blotting, Western | 17 | 0.0 |
Calcium/metabolism | 17 | 1.0 |
Disease Models, Animal | 2 | 0.0 |
Down-Regulation | 7 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 24 | 0.0 |
Immunoglobulin M/metabolism | 6 | 7.0 |
Mice | 147 | 0.0 |
NAD+ Nucleosidase/biosynthesis | 2 | 28.0 |
Phosphorylation | 43 | 0.0 |
Precipitin Tests | 12 | 0.0 |
Signal Transduction | 34 | 0.0 |
Tyrosine/metabolism | 18 | 1.0 |
Up-Regulation | 5 | 0.0 |
*Leukemic Infiltration | 2 | 18.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 2 | 1.0 |
B-Lymphocytes/*physiology | 17 | 11.0 |
Mice, Inbred C57BL | 13 | 0.0 |
Mice, Inbred CBA | 4 | 1.0 |
Protein-Tyrosine Kinase/*physiology | 4 | 2.0 |
Receptors, Antigen, B-Cell/physiology | 5 | 15.0 |
Diagnosis, Differential | 33 | 1.0 |
Neutrophils/drug effects | 3 | 5.0 |
Recurrence | 20 | 1.0 |
Antigens, CD19/*metabolism/physiology | 2 | 100.0 |
Cell Division/drug effects | 30 | 0.0 |
Antigens, CD/*immunology | 29 | 6.0 |
Antigens, Differentiation, B-Lymphocyte/*immunology | 23 | 31.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
Signal Transduction/immunology | 13 | 3.0 |
Case-Control Studies | 26 | 0.0 |
Interferon Type II/pharmacology | 6 | 1.0 |
Interferon-alpha/pharmacology | 2 | 2.0 |
Tumor Necrosis Factor-alpha/pharmacology | 4 | 0.0 |
Leukemia, Lymphocytic, Chronic/immunology/*pathology | 3 | 50.0 |
Lymph Nodes/immunology/*pathology | 2 | 13.0 |
Tumor Markers, Biological/analysis | 18 | 2.0 |
*Chromosomes, Human, Pair 11 | 11 | 1.0 |
*Chromosomes, Human, Pair 14 | 9 | 4.0 |
Clone Cells/immunology/pathology | 2 | 15.0 |
Cytogenetic Analysis | 5 | 4.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
*Translocation, Genetic | 38 | 4.0 |
Trisomy | 7 | 6.0 |
Age Factors | 22 | 0.0 |
Antigens, CD/*biosynthesis/immunology | 2 | 8.0 |
Plasma Cells/immunology | 4 | 14.0 |
Antigen Presentation | 7 | 2.0 |
Antigens, CD/analysis/*metabolism | 2 | 13.0 |
Asthma/*immunology | 5 | 5.0 |
Hypersensitivity, Immediate/*immunology | 4 | 14.0 |
Aging/immunology | 4 | 7.0 |
*Lymphocyte Count | 8 | 16.0 |
Nutritional Status | 2 | 1.0 |
Antibodies, Monoclonal | 72 | 2.0 |
Bone Marrow Cells/immunology | 2 | 5.0 |
Bone Marrow Purging/*methods | 8 | 22.0 |
Bone Marrow Transplantation | 10 | 3.0 |
Cell Separation/*methods | 17 | 11.0 |
Hematopoietic Stem Cells | 4 | 6.0 |
Immunomagnetic Separation | 11 | 10.0 |
Leukapheresis | 9 | 8.0 |
Mice, Inbred NOD | 10 | 4.0 |
Mice, SCID | 32 | 4.0 |
Polymerase Chain Reaction/methods | 7 | 0.0 |
Transplantation, Autologous | 20 | 5.0 |
Chromosome Mapping | 7 | 0.0 |
Genes, bcl-2/genetics | 2 | 5.0 |
Linkage Disequilibrium | 2 | 0.0 |
T-Lymphocytes/cytology/*metabolism | 2 | 6.0 |
Antigens, CD | 16 | 12.0 |
Immunity, Cellular | 20 | 3.0 |
Interleukin-1/blood | 3 | 1.0 |
Interleukin-6/blood | 4 | 0.0 |
Lymphocyte Subsets/*immunology | 27 | 21.0 |
Tumor Necrosis Factor-alpha/metabolism | 8 | 1.0 |
Antigens, Differentiation/analysis | 39 | 12.0 |
Cattle | 3 | 0.0 |
Cell Culture Techniques/methods | 3 | 1.0 |
Cells, Cultured | 84 | 0.0 |
Colony-Forming Units Assay | 19 | 3.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 9 | 5.0 |
Stem Cell Factor/pharmacology | 4 | 2.0 |
Blotting, Southern | 30 | 1.0 |
*Chromosome Aberrations | 15 | 2.0 |
Chromosome Banding | 9 | 1.0 |
Immunoenzyme Techniques | 28 | 0.0 |
Immunoglobulins/analysis | 12 | 4.0 |
Lymphoma, B-Cell/*genetics/pathology | 2 | 8.0 |
Antigens, CD20/analysis | 6 | 13.0 |
Antigens, CD5/analysis | 7 | 15.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 47 | 27.0 |
*Cell Adhesion Molecules | 30 | 14.0 |
*Flow Cytometry | 20 | 12.0 |
Fluorescein-5-isothiocyanate | 13 | 9.0 |
HLA-DR Antigens/analysis | 42 | 6.0 |
*Immunophenotyping | 32 | 17.0 |
*Lectins | 31 | 17.0 |
Lymphoma, B-Cell/*immunology | 9 | 23.0 |
Phycoerythrin | 8 | 40.0 |
Receptors, Complement 3d/analysis | 4 | 21.0 |
Receptors, IgE/analysis | 2 | 6.0 |
Antigens, CD/analysis/immunology | 7 | 14.0 |
B-Lymphocytes | 10 | 5.0 |
CD4-Positive T-Lymphocytes | 3 | 1.0 |
CD8-Positive T-Lymphocytes | 3 | 4.0 |
Fluorescent Dyes | 10 | 2.0 |
Italy | 3 | 0.0 |
Killer Cells, Natural | 6 | 14.0 |
*Lymphocyte Subsets | 21 | 24.0 |
Doxorubicin/administration & dosage | 6 | 3.0 |
Melphalan/administration & dosage | 2 | 4.0 |
Antigens, CD19/genetics/metabolism/*physiology | 3 | 100.0 |
Cytotoxicity Tests, Immunologic | 5 | 1.0 |
Dose-Response Relationship, Immunologic | 6 | 1.0 |
Intracellular Fluid/*immunology | 2 | 28.0 |
Leukocytes, Mononuclear/immunology | 8 | 2.0 |
Lymphocyte Activation/genetics | 4 | 4.0 |
Neutrophils/immunology | 6 | 3.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Transfection | 19 | 0.0 |
Antigens, CD19 | 125 | 77.0 |
Antigens, CD2 | 10 | 2.0 |
Antigens, CD3 | 9 | 1.0 |
Antigens, Differentiation, B-Lymphocyte | 12 | 32.0 |
B-Lymphocytes/immunology | 47 | 6.0 |
Erythrocytes | 3 | 6.0 |
Hematopoietic Stem Cell Transplantation/*adverse effects | 4 | 10.0 |
Histocompatibility Testing | 7 | 0.0 |
Lectins | 2 | 2.0 |
Sheep | 2 | 0.0 |
Tissue Donors | 5 | 1.0 |
Transplantation, Homologous | 11 | 1.0 |
*Antibody Formation | 6 | 6.0 |
Antigens, Surface/analysis | 37 | 8.0 |
*Immunity, Cellular | 5 | 3.0 |
Postoperative Period | 9 | 2.0 |
Immunoglobulin Variable Region/genetics | 6 | 5.0 |
Immunoglobulins, Heavy-Chain/genetics | 14 | 8.0 |
In Situ Hybridization, Fluorescence | 20 | 0.0 |
Prognosis | 53 | 0.0 |
Tumor Markers, Biological/metabolism | 4 | 1.0 |
Antibodies, Anti-Idiotypic/pharmacology | 3 | 9.0 |
Calcium/antagonists & inhibitors/metabolism | 2 | 18.0 |
Epitopes, B-Lymphocyte/immunology | 2 | 12.0 |
Heat | 3 | 0.0 |
Immunoglobulin M/immunology | 7 | 5.0 |
Intracellular Fluid/metabolism | 3 | 2.0 |
Lymphocyte Activation/immunology | 11 | 2.0 |
Protein Binding/immunology | 4 | 2.0 |
Signal Transduction/*immunology | 15 | 3.0 |
Maternal-Fetal Exchange | 2 | 1.0 |
Statistics, Nonparametric | 13 | 1.0 |
B-Lymphocytes/immunology/pathology | 10 | 22.0 |
Bone Marrow/*pathology | 17 | 11.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 15 | 22.0 |
Membrane Glycoproteins/analysis | 4 | 1.0 |
Neoplasm Transplantation | 17 | 1.0 |
Plasma Cells/pathology | 3 | 7.0 |
Proteoglycans/analysis | 2 | 14.0 |
RNA, Messenger/analysis | 11 | 0.0 |
Transplantation, Heterologous | 12 | 1.0 |
Antibodies, Monoclonal/adverse effects/*therapeutic use | 2 | 5.0 |
Immunotherapy | 9 | 2.0 |
Flow Cytometry/*standards | 2 | 15.0 |
Immunophenotyping/*standards | 4 | 33.0 |
Reference Values | 37 | 0.0 |
Saudi Arabia | 4 | 9.0 |
Antigens, CD56 | 10 | 14.0 |
Antiretroviral Therapy, Highly Active | 2 | 0.0 |
B-Lymphocytes/cytology | 8 | 10.0 |
Biological Markers | 27 | 1.0 |
CD4 Lymphocyte Count | 12 | 0.0 |
Prospective Studies | 25 | 0.0 |
Receptors, IgG | 5 | 3.0 |
Viral Load | 2 | 0.0 |
Antigens, CD/metabolism | 27 | 3.0 |
HLA-DR Antigens/metabolism | 7 | 4.0 |
Translocation, Genetic/*genetics | 6 | 2.0 |
Antigens, CD45 | 12 | 5.0 |
Immunologic Memory | 8 | 2.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 3 | 1.0 |
Gene Frequency | 3 | 0.0 |
Lymphocyte Subsets/*classification/immunology | 2 | 66.0 |
Occupational Exposure/*adverse effects | 5 | 5.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Antigens, CD4/biosynthesis | 4 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 5 | 17.0 |
Antineoplastic Agents/therapeutic use | 5 | 1.0 |
B-Lymphocytes/metabolism | 8 | 4.0 |
Blood Cells/*cytology | 3 | 42.0 |
Bone Marrow Cells/*cytology | 4 | 8.0 |
*Integrin alpha Chains | 2 | 7.0 |
Lymphocyte Subsets/*cytology | 4 | 17.0 |
Receptors, Interleukin-2/biosynthesis | 5 | 4.0 |
Acute Disease | 62 | 2.0 |
Antigens, CD34/analysis | 22 | 3.0 |
Bone Marrow/pathology | 30 | 7.0 |
Cell Differentiation/drug effects | 15 | 1.0 |
Dendritic Cells/cytology/*immunology | 5 | 8.0 |
Leukemia, Lymphocytic, Acute/*pathology | 8 | 40.0 |
Leukemia, Myeloid, Philadelphia-Positive/genetics/pathology | 2 | 66.0 |
T-Lymphocyte Subsets/immunology | 14 | 3.0 |
Antigens, CD/*analysis/genetics | 4 | 16.0 |
Antigens, Surface/*analysis/genetics | 2 | 50.0 |
B-Lymphocyte Subsets/*immunology | 16 | 20.0 |
Chromosomes, Human, Pair 11/ultrastructure | 2 | 25.0 |
Chromosomes, Human, Pair 12 | 2 | 1.0 |
Cluster Analysis | 2 | 1.0 |
NAD+ Nucleosidase/analysis | 5 | 11.0 |
Sequence Deletion | 2 | 0.0 |
Tumor Stem Cells/*immunology | 2 | 8.0 |
Antibodies, Monoclonal/immunology/*therapeutic use | 3 | 9.0 |
Antibody Affinity | 4 | 2.0 |
Antigens, CD19/*immunology | 26 | 83.0 |
Antigens, CD20/*immunology | 4 | 33.0 |
Antigens, Neoplasm/*immunology | 9 | 5.0 |
Mice, Nude | 7 | 0.0 |
*Radioimmunotherapy | 5 | 19.0 |
Aged, 80 and over | 101 | 1.0 |
B-Lymphocytes/*cytology | 12 | 19.0 |
Leukemia, B-Cell, Chronic/*pathology | 4 | 23.0 |
Severity of Illness Index | 6 | 0.0 |
Amino Acid Sequence | 24 | 0.0 |
B-Lymphocytes/*immunology/*metabolism | 3 | 17.0 |
Binding Sites | 6 | 0.0 |
Cell Adhesion | 14 | 1.0 |
Molecular Sequence Data | 76 | 0.0 |
Protein Binding | 17 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Antigens, CD34 | 39 | 6.0 |
Graft Survival | 10 | 2.0 |
*Hematopoietic Stem Cell Transplantation | 19 | 4.0 |
Multiple Myeloma/*therapy | 3 | 17.0 |
Pilot Projects | 6 | 0.0 |
Combined Modality Therapy | 24 | 2.0 |
Fatal Outcome | 17 | 2.0 |
Neoplasm Proteins/analysis | 10 | 3.0 |
Neoplasm Recurrence, Local | 5 | 1.0 |
*Linkage (Genetics) | 2 | 0.0 |
*X Chromosome | 3 | 0.0 |
Blotting, Northern | 14 | 0.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
T-Lymphocytes/metabolism | 5 | 1.0 |
Antigens, Surface/*metabolism | 4 | 6.0 |
Antineoplastic Agents/*pharmacology | 5 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Chromosomes, Human, Pair 14/genetics | 2 | 2.0 |
Cyclophosphamide/pharmacology | 3 | 7.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Translocation, Genetic | 24 | 3.0 |
Vincristine/pharmacology | 2 | 3.0 |
Mutation | 9 | 0.0 |
B-Lymphocytes/pathology | 15 | 17.0 |
Cell Differentiation | 69 | 2.0 |
Coculture Techniques | 12 | 1.0 |
Leukocytes, Mononuclear/immunology/*pathology | 2 | 33.0 |
Spleen/cytology | 8 | 4.0 |
Cell Line, Transformed | 15 | 0.0 |
Lymphocytes/*metabolism | 6 | 3.0 |
Mice, Inbred BALB C | 24 | 0.0 |
B-Lymphocytes/metabolism/*pathology | 3 | 42.0 |
DNA Nucleotidylexotransferase/biosynthesis | 3 | 60.0 |
HLA-DR Antigens/biosynthesis | 4 | 4.0 |
Hematopoietic Stem Cells/metabolism/*pathology | 2 | 18.0 |
Syndrome | 6 | 0.0 |
Tomography, X-Ray Computed | 5 | 0.0 |
Antigens, CD/genetics | 5 | 3.0 |
Lymphocyte Subsets/cytology/immunology | 4 | 44.0 |
Antigens, Neoplasm/immunology | 12 | 9.0 |
Fetal Blood/*immunology | 9 | 11.0 |
*Immunotherapy | 5 | 3.0 |
T-Lymphocytes, Cytotoxic/immunology | 6 | 1.0 |
*Lymphocyte Activation | 29 | 2.0 |
Antibodies, Monoclonal/*therapeutic use | 13 | 4.0 |
Clinical Trials | 6 | 0.0 |
Lymphoma, Non-Hodgkin/immunology/*therapy | 5 | 55.0 |
Breast Neoplasms/therapy | 2 | 13.0 |
Cross-Over Studies | 4 | 0.0 |
Hematopoietic Stem Cells/cytology/immunology | 2 | 6.0 |
Lymphoma, Non-Hodgkin/therapy | 3 | 12.0 |
Antigens, CD19/immunology | 19 | 48.0 |
Crohn Disease/*immunology | 2 | 5.0 |
Receptors, Antigen, T-Cell, gamma-delta/immunology | 2 | 9.0 |
B-Lymphocytes/chemistry | 2 | 8.0 |
DNA Fingerprinting | 3 | 2.0 |
DNA, Neoplasm/analysis | 12 | 1.0 |
Epstein-Barr Virus Infections | 2 | 66.0 |
Gene Rearrangement, B-Lymphocyte, Light Chain/*genetics | 2 | 100.0 |
Leukemia, Pre-B-Cell/*immunology/pathology | 2 | 66.0 |
Analysis of Variance | 8 | 0.0 |
Antigens, CD/immunology | 34 | 7.0 |
Interleukin-6/*metabolism | 2 | 1.0 |
Neoplasm Staging | 11 | 0.0 |
Burkitt Lymphoma/*genetics | 2 | 6.0 |
Chromosomes, Human, Pair 22 | 3 | 1.0 |
Chromosomes, Human, Pair 8 | 8 | 6.0 |
RNA, Viral/analysis | 5 | 1.0 |
Antigens, CD7/*metabolism | 2 | 20.0 |
Chromosomes, Human, Pair 21 | 4 | 3.0 |
Gene Rearrangement | 25 | 5.0 |
Oncogene Proteins, Fusion/*genetics | 3 | 1.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Drug Carriers | 3 | 2.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Liposomes/*chemistry | 2 | 25.0 |
*Adaptor Proteins, Signal Transducing | 4 | 0.0 |
Calcium/*metabolism | 6 | 0.0 |
Enzyme Activation | 13 | 0.0 |
Immunoblotting | 8 | 0.0 |
*Membrane Proteins | 6 | 0.0 |
Phosphoproteins/*metabolism | 4 | 0.0 |
T-Lymphocytes | 4 | 1.0 |
*CD4 Lymphocyte Count | 5 | 2.0 |
CD4-Positive T-Lymphocytes/immunology | 12 | 1.0 |
CD8-Positive T-Lymphocytes/immunology | 4 | 0.0 |
Cohort Studies | 6 | 0.0 |
RNA, Viral/blood | 2 | 0.0 |
Virus Replication/drug effects | 2 | 0.0 |
Antigens, CD45/*analysis | 2 | 4.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 24 | 4.0 |
Asparaginase/administration & dosage | 3 | 14.0 |
Methotrexate/administration & dosage | 4 | 4.0 |
Cytomegalovirus Infections/epidemiology | 2 | 22.0 |
Incidence | 7 | 0.0 |
Neutrophils | 2 | 2.0 |
Risk | 4 | 0.0 |
Antigens, Neoplasm/analysis | 35 | 10.0 |
Glycoproteins/analysis | 2 | 3.0 |
Leukemia, B-Cell, Chronic/*diagnosis/immunology | 2 | 40.0 |
CD8-Positive T-Lymphocytes/metabolism | 5 | 6.0 |
Cytokines/*biosynthesis | 4 | 1.0 |
Immune System/*physiopathology | 3 | 20.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Monocytes/*metabolism | 2 | 0.0 |
Lymphocytes/immunology/pathology | 4 | 16.0 |
Antigens, CD20/biosynthesis | 5 | 29.0 |
Follow-Up Studies | 27 | 0.0 |
Immunoglobulins, kappa-Chain/biosynthesis | 3 | 37.0 |
Lymph Nodes/*pathology | 5 | 5.0 |
Antigens, CD95/metabolism | 3 | 2.0 |
Antigens, Differentiation/metabolism | 6 | 4.0 |
Germinal Center/*immunology | 2 | 33.0 |
Immunoglobulin Class Switching | 3 | 15.0 |
NAD+ Nucleosidase/metabolism | 3 | 10.0 |
Tonsil/immunology | 5 | 7.0 |
Antigens, CD34/*immunology | 9 | 12.0 |
Culture Media, Serum-Free | 6 | 1.0 |
Cytokines/*pharmacology | 4 | 1.0 |
Growth Substances/*pharmacology | 3 | 0.0 |
Interleukin-3/pharmacology | 7 | 2.0 |
Interleukin-6/pharmacology | 4 | 1.0 |
Stem Cells/*immunology | 4 | 18.0 |
Thrombopoietin/pharmacology | 2 | 3.0 |
Antibodies, Monoclonal/therapeutic use | 10 | 5.0 |
Disease Progression | 12 | 0.0 |
Hematopoietic Stem Cell Transplantation | 7 | 3.0 |
Risk Factors | 13 | 0.0 |
B-Lymphocytes/*cytology/immunology | 6 | 18.0 |
Health Status | 2 | 2.0 |
*Immunologic Memory | 2 | 1.0 |
Antigens, CD19/genetics/*immunology | 2 | 100.0 |
Immunomagnetic Separation/*methods | 2 | 11.0 |
Blood Proteins/analysis | 2 | 1.0 |
Bronchoalveolar Lavage Fluid/*cytology/immunology | 2 | 22.0 |
Eosinophils/immunology | 3 | 5.0 |
Radioimmunoassay | 3 | 0.0 |
HIV Antibodies/blood | 2 | 2.0 |
*HIV-1/immunology | 2 | 6.0 |
Membrane Glycoproteins/metabolism | 4 | 0.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 2 | 5.0 |
Cytokines/biosynthesis | 6 | 1.0 |
Lymphocyte Subsets/drug effects/immunology | 4 | 21.0 |
Antigens, Differentiation/biosynthesis/immunology | 2 | 50.0 |
*Immunoconjugates | 2 | 0.0 |
Immunophenotyping/methods | 8 | 16.0 |
*Antigens, CD34 | 2 | 2.0 |
Fetal Blood/*cytology/immunology | 4 | 17.0 |
Spleen/immunology | 3 | 1.0 |
Lymphocytes/pathology | 3 | 3.0 |
Splenectomy | 2 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 20 | 33.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 11 | 5.0 |
Cell Cycle | 19 | 1.0 |
Cell Membrane Permeability | 3 | 1.0 |
DNA/analysis | 7 | 0.0 |
Fluorescent Dyes/chemistry | 2 | 8.0 |
Formaldehyde/chemistry | 2 | 33.0 |
Polymers/chemistry | 2 | 8.0 |
Antigens, CD34/*analysis | 9 | 3.0 |
Antigens, Differentiation/*analysis | 10 | 5.0 |
Gene Expression | 29 | 0.0 |
Gene Therapy | 2 | 0.0 |
Genetic Vectors | 6 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 6 | 1.0 |
Hematopoietic Stem Cells/immunology/*metabolism | 2 | 11.0 |
NAD+ Nucleosidase/*analysis | 2 | 8.0 |
Retroviridae/*genetics | 3 | 2.0 |
*Transfection | 2 | 0.0 |
ROC Curve | 2 | 1.0 |
Antigens, CD/analysis/genetics | 4 | 13.0 |
T-Lymphocytes/immunology | 31 | 2.0 |
CD4-Positive T-Lymphocytes/pathology | 5 | 6.0 |
CD8-Positive T-Lymphocytes/pathology | 6 | 13.0 |
Cell Movement | 5 | 0.0 |
Double-Blind Method | 12 | 0.0 |
Interleukin-8/*analysis | 3 | 21.0 |
Macrophages/pathology | 4 | 3.0 |
Monocytes/pathology | 2 | 5.0 |
Observer Variation | 3 | 2.0 |
RANTES/*analysis | 2 | 33.0 |
Statistics | 2 | 0.0 |
T-Lymphocytes/pathology | 7 | 6.0 |
Antibody Formation/*physiology | 2 | 18.0 |
Immunity, Cellular/*physiology | 4 | 21.0 |
Life Style | 2 | 1.0 |
Questionnaires | 4 | 0.0 |
Immunoglobulin A/blood | 4 | 3.0 |
Chromosome Aberrations | 22 | 4.0 |
Chromosome Disorders | 12 | 3.0 |
*Chromosomes, Human, Pair 21 | 6 | 3.0 |
*Chromosomes, Human, Pair 8 | 9 | 3.0 |
Leukemic Infiltration | 4 | 30.0 |
Hematopoiesis | 13 | 5.0 |
Hematopoietic Stem Cells/*immunology | 13 | 9.0 |
*Electromagnetic Fields | 2 | 6.0 |
Kinetics | 12 | 0.0 |
*Chromosomes, Human, Pair 1 | 5 | 1.0 |
*Renal Dialysis | 6 | 1.0 |
Antigens, CD19/biosynthesis | 5 | 41.0 |
Antineoplastic Agents/*therapeutic use | 12 | 3.0 |
CD4-Positive T-Lymphocytes/metabolism | 2 | 1.0 |
HIV/metabolism | 2 | 13.0 |
HIV Seropositivity/*immunology | 3 | 3.0 |
Leukocytes, Mononuclear/virology | 3 | 2.0 |
Adjuvants, Immunologic/*therapeutic use | 2 | 2.0 |
In Situ Hybridization | 8 | 0.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Tissue Fixation | 3 | 3.0 |
Lymphocyte Activation/drug effects | 14 | 2.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 17 | 0.0 |
Aging | 3 | 0.0 |
Blood Donors | 6 | 2.0 |
Body Weight | 2 | 0.0 |
Cell Count | 15 | 1.0 |
Hematopoietic Stem Cells/*cytology/immunology | 7 | 8.0 |
Sex Characteristics | 6 | 1.0 |
Lymphatic Metastasis | 3 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 13 | 3.0 |
Peroxidase/metabolism | 2 | 1.0 |
*B-Lymphocyte Subsets | 3 | 37.0 |
*T-Lymphocyte Subsets | 6 | 8.0 |
Antigens, CD/physiology | 3 | 1.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Integrin alpha4beta1 | 3 | 3.0 |
Jurkat Cells | 7 | 0.0 |
Mice, Transgenic | 15 | 0.0 |
Antibodies/immunology | 4 | 1.0 |
Burkitt Lymphoma/immunology | 4 | 22.0 |
Microscopy, Confocal | 3 | 0.0 |
Antigens, CD/blood | 25 | 10.0 |
Hydrocortisone/blood | 7 | 1.0 |
Immunoglobulin G/blood | 7 | 2.0 |
Immunoglobulin M/blood | 8 | 6.0 |
*Monitoring, Immunologic | 2 | 66.0 |
Sensitivity and Specificity | 19 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/administration & dosage | 2 | 6.0 |
Immunoglobulin E/*blood | 2 | 3.0 |
Immunoglobulins/blood | 12 | 13.0 |
Interleukins/blood | 3 | 7.0 |
*Thoracic Surgical Procedures | 2 | 40.0 |
Antigens, CD13/analysis | 3 | 12.0 |
Antigens, CD2/analysis | 6 | 15.0 |
Antigens, CD56/analysis | 6 | 9.0 |
Leukemia, Myelocytic, Acute/*immunology | 3 | 8.0 |
Neoplasm, Residual/*diagnosis | 4 | 9.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
T-Lymphocytes/*immunology | 28 | 1.0 |
DNA/*analysis | 5 | 2.0 |
*Chromosomes, Human, Pair 17 | 2 | 0.0 |
DNA-Binding Proteins/genetics | 8 | 0.0 |
Fusion Proteins, bcr-abl/genetics | 3 | 7.0 |
Genotype | 17 | 0.0 |
*Proto-Oncogenes | 4 | 0.0 |
*Transcription Factors | 16 | 0.0 |
Dendritic Cells/immunology/*pathology | 2 | 13.0 |
Serine Endopeptidases/analysis | 2 | 5.0 |
T-Lymphocytes, Helper-Inducer/immunology | 2 | 1.0 |
Antigens, CD/immunology/metabolism | 6 | 11.0 |
Antigens, Differentiation, B-Lymphocyte/immunology/metabolism | 3 | 33.0 |
B-Lymphocytes/cytology/*immunology | 10 | 14.0 |
Oncogene Proteins/immunology | 2 | 66.0 |
*Protein-Tyrosine Kinase | 2 | 0.0 |
*Proto-Oncogene Proteins | 6 | 0.0 |
Chemotaxis, Leukocyte | 5 | 2.0 |
Lymphocyte Subsets | 24 | 12.0 |
Neutrophils/physiology | 2 | 1.0 |
Phagocytosis | 3 | 0.0 |
Remission, Spontaneous | 2 | 2.0 |
Enzyme Precursors/metabolism | 7 | 5.0 |
Genetic Complementation Test | 2 | 0.0 |
Models, Biological | 8 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 11 | 1.0 |
Proto-Oncogene Proteins/metabolism | 7 | 0.0 |
src-Family Kinases/*metabolism | 6 | 3.0 |
Infusions, Intravenous | 9 | 1.0 |
B-Lymphocytes/physiology | 4 | 6.0 |
Immune Tolerance | 6 | 2.0 |
Polysaccharides, Bacterial/*immunology | 2 | 8.0 |
Streptococcus pneumoniae/*immunology | 2 | 6.0 |
Lymphocyte Subsets/*classification | 2 | 66.0 |
Leukocytes, Mononuclear/pathology | 2 | 10.0 |
Lymphocyte Culture Test, Mixed | 14 | 2.0 |
Autoantibodies/analysis | 3 | 1.0 |
Biological Markers/analysis | 11 | 1.0 |
Lupus Erythematosus, Systemic/*immunology | 2 | 1.0 |
Membrane Glycoproteins/*analysis | 2 | 1.0 |
*Bone Marrow Transplantation | 18 | 4.0 |
Flow Cytometry/methods | 21 | 8.0 |
Immunoglobulin D/blood | 2 | 28.0 |
Antibodies, Monoclonal/immunology/pharmacology | 2 | 2.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
*Membrane Glycoproteins | 6 | 0.0 |
Microscopy, Electron | 18 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Dose-Response Relationship, Radiation | 3 | 0.0 |
*Gamma Rays | 2 | 4.0 |
Micronucleus Tests | 2 | 4.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*blood/complications | 2 | 20.0 |
Annexin A5/metabolism | 3 | 3.0 |
*Apoptosis | 10 | 0.0 |
Oxidation-Reduction | 2 | 0.0 |
Lymphoma, Non-Hodgkin/*therapy | 3 | 27.0 |
*Tumor Cells, Cultured | 5 | 7.0 |
Lymphoma/*diagnosis/immunology | 2 | 66.0 |
Bone Marrow Cells/pathology | 4 | 7.0 |
Immunomagnetic Separation/methods | 3 | 27.0 |
Leukapheresis/methods | 2 | 12.0 |
*Lymphocyte Depletion | 3 | 3.0 |
Lymphoma, Mucosa-Associated Lymphoid Tissue/*pathology | 2 | 66.0 |
Neoplasm Invasiveness | 5 | 0.0 |
Antibody Formation | 10 | 2.0 |
Antigens, CD/*blood | 9 | 5.0 |
Autoantibodies/*blood | 2 | 0.0 |
Complement 3/analysis | 3 | 0.0 |
Complement 4/analysis | 2 | 0.0 |
HLA-DR Antigens/blood | 5 | 9.0 |
Th1 Cells/immunology | 2 | 1.0 |
Antigens, CD19/blood | 9 | 69.0 |
Antigens, CD3/blood | 2 | 6.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 4 | 1.0 |
Antigens, CD19/metabolism | 17 | 70.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Immunoglobulins, Surface/metabolism | 4 | 21.0 |
K562 Cells | 3 | 0.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Phosphotyrosine/*metabolism | 2 | 3.0 |
Antibody Specificity | 20 | 1.0 |
Cross Reactions | 2 | 0.0 |
Leukocytes/immunology | 2 | 1.0 |
Linear Models | 3 | 0.0 |
Neoplasm, Residual/diagnosis | 2 | 14.0 |
Antibodies, Monoclonal/*diagnostic use | 13 | 6.0 |
Chromosomes, Human, Pair 14 | 9 | 5.0 |
Gene Rearrangement/genetics | 6 | 13.0 |
Antigens, CD45/*metabolism | 2 | 6.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Immune System/*physiology | 4 | 6.0 |
Interferon Type II/*blood | 2 | 6.0 |
Lymphocytes/immunology/*radiation effects | 2 | 66.0 |
Biological Markers/*analysis | 2 | 1.0 |
Blood Preservation | 2 | 2.0 |
Drug Stability | 2 | 0.0 |
Fetal Blood/*cytology | 11 | 5.0 |
Lymphocytes/*immunology | 21 | 5.0 |
Antigens, CD19/*metabolism | 14 | 87.0 |
Antigens, CD/*drug effects | 2 | 28.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Interleukin-2/biosynthesis | 6 | 1.0 |
Killer Cells, Natural/*drug effects | 2 | 6.0 |
Lymphocyte Subsets/*drug effects | 9 | 45.0 |
T-Lymphocyte Subsets/drug effects | 2 | 10.0 |
Immunoglobulins, Light-Chain/genetics | 3 | 8.0 |
Japan | 6 | 0.0 |
Liver/pathology | 3 | 1.0 |
Receptors, Antigen, B-Cell/analysis | 3 | 16.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 3 | 4.0 |
Solubility | 5 | 0.0 |
Up-Regulation/genetics/immunology | 2 | 3.0 |
Antigens, Differentiation/*blood | 2 | 11.0 |
Antigens, Neoplasm/*blood | 2 | 4.0 |
B-Lymphocyte Subsets/*pathology | 2 | 66.0 |
Base Sequence | 67 | 0.0 |
Clone Cells/pathology | 5 | 8.0 |
Genes, Immunoglobulin | 15 | 8.0 |
Myeloma Proteins/genetics | 2 | 66.0 |
Tumor Markers, Biological/*blood | 4 | 0.0 |
Antigens, CD40/immunology | 2 | 3.0 |
Immunoglobulin M/biosynthesis | 6 | 6.0 |
Lymphoid Tissue/immunology | 2 | 5.0 |
Antigens, CD19/genetics/*physiology | 5 | 100.0 |
Antigens, Differentiation, B-Lymphocyte/*metabolism | 9 | 25.0 |
*Autoimmunity | 3 | 4.0 |
Cross-Linking Reagents | 3 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Receptors, Antigen, B-Cell/metabolism | 5 | 10.0 |
Antigens, Surface/*blood | 2 | 13.0 |
Cell Survival | 14 | 1.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
Intercellular Adhesion Molecule-1/analysis | 3 | 2.0 |
Interleukin-10/*pharmacology | 3 | 3.0 |
Receptors, IgG/analysis | 6 | 9.0 |
Receptors, Interleukin-2/analysis | 19 | 7.0 |
Recombinant Proteins/pharmacology | 12 | 0.0 |
Leukemia, Hairy Cell/*diagnosis/immunology | 2 | 66.0 |
B-Lymphocytes/immunology/metabolism/pathology | 3 | 37.0 |
Cell Differentiation/genetics/immunology | 3 | 3.0 |
B-Lymphocytes/immunology/*metabolism | 7 | 12.0 |
*Nuclear Proteins | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 3 | 1.0 |
Transcription, Genetic | 8 | 0.0 |
Tyrosine/chemistry | 3 | 2.0 |
Calcium Signaling/immunology | 3 | 13.0 |
Cell Survival/drug effects | 4 | 0.0 |
Cytotoxicity, Immunologic/drug effects | 2 | 1.0 |
Immunoglobulin G/therapeutic use | 2 | 5.0 |
Antigens, CD19/*blood | 6 | 85.0 |
Hypereosinophilic Syndrome/*complications | 2 | 100.0 |
Cancer Vaccines | 2 | 18.0 |
Immunotherapy, Adoptive/methods | 2 | 16.0 |
Complement Activation | 3 | 1.0 |
Mice, Knockout | 9 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 3 | 0.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Receptors, Antigen, B-Cell/*metabolism | 7 | 8.0 |
Lymphoma, B-Cell | 3 | 8.0 |
Proto-Oncogene Proteins/*metabolism | 6 | 0.0 |
Cytoplasm/immunology/metabolism | 2 | 16.0 |
DNA Mutational Analysis | 3 | 0.0 |
Phosphatidylinositol Phosphates/metabolism | 2 | 4.0 |
Phosphoric Monoester Hydrolases/metabolism | 3 | 3.0 |
Bronchoalveolar Lavage Fluid/*cytology | 6 | 13.0 |
Mast Cells/pathology | 3 | 8.0 |
*Immunocompetence | 2 | 13.0 |
*Nutritional Status | 6 | 7.0 |
Antibodies, Monoclonal/immunology | 43 | 2.0 |
Antigens, CD28/*immunology | 3 | 2.0 |
Antigens, CD3/*immunology | 14 | 13.0 |
Immunotherapy, Adoptive | 2 | 2.0 |
Lymphoma, B-Cell/immunology/therapy | 2 | 66.0 |
Tissue Distribution | 4 | 0.0 |
Infant, Premature, Diseases/*immunology | 2 | 50.0 |
Antibodies, Viral/blood | 4 | 3.0 |
Antigens, CD19/genetics | 6 | 85.0 |
Antigens, Differentiation, B-Lymphocyte/genetics | 2 | 8.0 |
Immunization | 4 | 1.0 |
Transcription Factors/genetics | 3 | 0.0 |
Reoperation | 3 | 2.0 |
Leukemia, Myeloid, Chronic/therapy | 2 | 14.0 |
Neoplasm, Residual | 6 | 6.0 |
Immunoglobulins, Heavy-Chain/*genetics | 9 | 6.0 |
Leukemia, Lymphocytic, Acute/*genetics | 3 | 3.0 |
Alternative Splicing | 2 | 0.0 |
Antibody Specificity/immunology | 2 | 3.0 |
Species Specificity | 6 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Monocytes/*cytology | 2 | 2.0 |
Clone Cells | 18 | 1.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Vaccination | 2 | 1.0 |
Antibodies/analysis | 3 | 2.0 |
Kidney Transplantation/*immunology | 5 | 2.0 |
Cell Cycle/immunology | 3 | 9.0 |
Erythrocyte Count | 2 | 2.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Rabbits | 6 | 0.0 |
Fetal Blood/cytology | 8 | 4.0 |
Macrophages/virology | 2 | 2.0 |
Organ Specificity | 5 | 0.0 |
Antigens, CD20/metabolism | 3 | 14.0 |
Antigens, Differentiation, B-Lymphocyte/metabolism | 12 | 20.0 |
Logistic Models | 2 | 0.0 |
Reproducibility of Results | 10 | 0.0 |
Biopsy | 19 | 1.0 |
Antigens, CD45/blood | 2 | 8.0 |
Antigens, CD3/immunology | 9 | 3.0 |
Cytokines/blood | 5 | 2.0 |
Genes, ras | 2 | 0.0 |
Killer Cells, Natural/*physiology | 2 | 4.0 |
Multivariate Analysis | 5 | 0.0 |
Leukemia, B-Cell/*immunology | 4 | 23.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 14 | 26.0 |
Receptors, Complement 3d/*immunology | 4 | 30.0 |
Receptors, IgG/immunology | 3 | 8.0 |
Lymphocyte Activation/*physiology | 4 | 4.0 |
Lymphoma, Non-Hodgkin/immunology/*pathology | 2 | 25.0 |
Fetal Blood/cytology/*immunology | 3 | 15.0 |
Hematopoietic Stem Cells/cytology/*immunology | 2 | 4.0 |
Bone Marrow Cells/metabolism | 2 | 2.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Hematopoietic Stem Cells/*metabolism | 5 | 3.0 |
T-Lymphocytes/*metabolism | 4 | 1.0 |
Antigens, CD19/physiology | 5 | 71.0 |
Protein Kinase C/physiology | 4 | 2.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Color | 2 | 7.0 |
Lymphocyte Subsets/chemistry/*cytology | 2 | 100.0 |
*Cholecystectomy | 2 | 20.0 |
*Cholecystectomy, Laparoscopic | 2 | 16.0 |
Immune Tolerance/immunology | 3 | 6.0 |
Postoperative Complications/*immunology | 2 | 12.0 |
Immunotoxins/*toxicity | 2 | 15.0 |
Ricin/*toxicity | 2 | 50.0 |
Blood/immunology | 2 | 15.0 |
*Leukapheresis | 3 | 8.0 |
Postoperative Complications | 3 | 2.0 |
Tumor Stem Cells/*pathology | 4 | 14.0 |
Antigens, Surface/*analysis | 18 | 9.0 |
Binding Sites, Antibody | 4 | 1.0 |
Quality Control | 2 | 1.0 |
Reference Standards | 5 | 2.0 |
Sex Factors | 8 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Fever/chemically induced | 2 | 14.0 |
Lymphoma, B-Cell/immunology/*therapy | 4 | 50.0 |
Blood Cells/immunology | 4 | 12.0 |
Dendritic Cells/*immunology | 7 | 2.0 |
Killer Cells, Natural/*immunology | 5 | 1.0 |
Antibodies, Monoclonal/metabolism | 5 | 1.0 |
Bronchoalveolar Lavage Fluid/*immunology | 2 | 6.0 |
Scleroderma, Systemic/*immunology | 3 | 11.0 |
B-Lymphocytes/*immunology/pathology | 8 | 19.0 |
Reed-Sternberg Cells/*immunology/pathology | 2 | 40.0 |
Plasma Cells | 3 | 42.0 |
Disease Susceptibility | 4 | 0.0 |
Antigens, CD/genetics/*metabolism | 2 | 2.0 |
Antigens, CD19/genetics/*metabolism | 3 | 100.0 |
Autoimmunity | 5 | 3.0 |
src-Family Kinases/metabolism | 4 | 2.0 |
*Chromosomes, Human, Pair 19 | 3 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics | 4 | 3.0 |
CHO Cells | 3 | 0.0 |
Hamsters | 4 | 0.0 |
Hela Cells | 3 | 0.0 |
Integrins/metabolism | 2 | 1.0 |
Antigens, CD5/*analysis | 6 | 17.0 |
Leukemia, B-Cell, Chronic/*immunology | 10 | 20.0 |
HIV-1/*immunology | 3 | 0.0 |
Immunoglobulins/metabolism | 3 | 2.0 |
Bone Marrow Cells/*immunology | 2 | 7.0 |
Filtration | 3 | 6.0 |
Macrophage-1 Antigen/metabolism | 2 | 2.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Antibodies, Bispecific/*therapeutic use | 2 | 20.0 |
Cell Death/drug effects | 2 | 1.0 |
*Cytotoxicity, Immunologic | 13 | 2.0 |
Immunotherapy/methods | 3 | 3.0 |
Lymphoma, B-Cell/*immunology/therapy | 2 | 50.0 |
*Cell Cycle Proteins | 5 | 0.0 |
Exons | 5 | 0.0 |
Isoenzymes/metabolism | 4 | 0.0 |
Molecular Weight | 11 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Phosphopeptides/metabolism | 2 | 6.0 |
Proteins/*metabolism | 4 | 0.0 |
Receptors, Antigen, B-Cell/metabolism/physiology | 2 | 28.0 |
Vanadates/pharmacology | 2 | 1.0 |
Interleukin-4/pharmacology | 4 | 1.0 |
Receptors, IgE/biosynthesis | 2 | 9.0 |
T-Lymphocytes/immunology/metabolism | 2 | 1.0 |
X Chromosome | 3 | 0.0 |
*Chromosomes, Human, Pair 16 | 2 | 0.0 |
Drug Resistance, Neoplasm | 4 | 0.0 |
Antigens, CD80/immunology | 2 | 3.0 |
HLA-DR Antigens/immunology | 12 | 5.0 |
Kidney Transplantation/*adverse effects | 3 | 5.0 |
*Chromosomes, Human, Pair 18 | 4 | 2.0 |
Lymphoma, B-Cell/*genetics | 3 | 4.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Proto-Oncogene Proteins/genetics | 6 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 2 | 1.0 |
Waldenstrom Macroglobulinemia/*genetics | 3 | 75.0 |
*src-Family Kinases | 2 | 4.0 |
Antigens, CD19/*genetics | 2 | 66.0 |
DNA/genetics/metabolism | 2 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Gene Expression Regulation | 9 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Lymphocytes/*physiology | 4 | 4.0 |
Diploidy | 3 | 2.0 |
*Gene Rearrangement | 11 | 4.0 |
*Genes, Immunoglobulin | 8 | 4.0 |
Bone Marrow/chemistry | 3 | 9.0 |
RNA, Messenger/*analysis | 4 | 0.0 |
Lymphoma, B-Cell/*therapy | 3 | 37.0 |
Genetic Markers | 4 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Lupus Erythematosus, Systemic/*genetics | 2 | 3.0 |
Cell Adhesion Molecules/*analysis | 3 | 2.0 |
Immunologic Memory/*immunology | 2 | 6.0 |
Demography | 3 | 2.0 |
Odds Ratio | 2 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 4 | 2.0 |
DNA-Binding Proteins/*genetics | 7 | 0.0 |
Lymphoma, B-Cell/genetics/*pathology | 2 | 20.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Sex Distribution | 2 | 0.0 |
Socioeconomic Factors | 2 | 1.0 |
Aminophylline/adverse effects/therapeutic use | 2 | 100.0 |
Asthma/*drug therapy/immunology/physiopathology | 2 | 33.0 |
Bronchodilator Agents/*therapeutic use | 2 | 22.0 |
Bronchospirometry | 2 | 100.0 |
Calcitonin/adverse effects/*therapeutic use | 2 | 100.0 |
Immunosuppressive Agents/pharmacology | 3 | 1.0 |
Injections, Intravenous | 4 | 0.0 |
Bone Marrow/*immunology | 11 | 18.0 |
Antigens, CD34/*blood/immunology | 2 | 66.0 |
Stem Cells/cytology/immunology | 2 | 11.0 |
Receptors, Antigen, T-Cell/immunology | 2 | 1.0 |
Thymoma/diagnosis/*immunology/therapy | 2 | 100.0 |
Thymus Neoplasms/diagnosis/*immunology/therapy | 2 | 100.0 |
Rats | 5 | 0.0 |
Antigens, CD19/*biosynthesis/genetics | 2 | 100.0 |
Cell Division/physiology | 3 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Multiple Myeloma/metabolism/*pathology | 2 | 10.0 |
Lymphocytes | 4 | 2.0 |
Phosphotyrosine/metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
Biological Transport | 6 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Introns | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Antigens, CD/*biosynthesis/genetics | 3 | 5.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
DNA, Viral/*analysis | 2 | 2.0 |
*CD4-CD8 Ratio | 3 | 4.0 |
Leukocyte Count/methods | 2 | 25.0 |
B-Lymphocyte Subsets | 6 | 50.0 |
Skin Tests | 4 | 2.0 |
Dimerization | 4 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Immunoglobulin Variable Region/genetics/immunology | 3 | 15.0 |
Models, Molecular | 2 | 0.0 |
Administration, Oral | 3 | 0.0 |
Herpesvirus 4, Human/*isolation & purification | 3 | 7.0 |
B-Lymphocytes/*pathology | 7 | 16.0 |
Hematopoietic Stem Cell Mobilization | 3 | 3.0 |
Hematopoietic Stem Cell Transplantation/methods | 2 | 11.0 |
Hematopoietic Stem Cells/*pathology | 9 | 12.0 |
B-Lymphocyte Subsets/immunology | 6 | 16.0 |
*Chromosomes, Human, Pair 9 | 2 | 0.0 |
DNA Primers | 9 | 0.0 |
Leukemia, Lymphocytic, Acute/*genetics/immunology/pathology | 2 | 66.0 |
Leukemia, Pre-B-Cell/*genetics/immunology/pathology | 2 | 100.0 |
Antigens, CD56/*metabolism | 2 | 14.0 |
Cytogenetics | 3 | 3.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 7 | 8.0 |
Killer Cells, Natural/immunology/pathology | 2 | 13.0 |
T-Lymphocytes/immunology/pathology | 5 | 8.0 |
Antigens, Surface/immunology | 5 | 2.0 |
Cell Differentiation/drug effects/immunology | 2 | 2.0 |
Intercellular Adhesion Molecule-1/immunology | 2 | 4.0 |
Cladribine/*therapeutic use | 4 | 44.0 |
Biological Markers/blood | 9 | 0.0 |
Cell Adhesion Molecules/physiology | 4 | 4.0 |
Fibroblasts/*physiology | 3 | 5.0 |
Gene Rearrangement, B-Lymphocyte | 10 | 18.0 |
Antibodies, Monoclonal/*pharmacology | 4 | 2.0 |
Antibodies, Neoplasm/*immunology | 3 | 13.0 |
Leukemia, B-Cell/*immunology/pathology | 2 | 40.0 |
Lymphocyte Activation/*drug effects | 7 | 2.0 |
Lymphoma, B-Cell/*immunology/pathology | 3 | 21.0 |
Tumor Cells, Cultured/immunology | 4 | 4.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Neprilysin/*metabolism | 2 | 14.0 |
Antigens, Surface/*immunology | 7 | 4.0 |
Isoantigens/immunology | 2 | 2.0 |
*Cell Fusion | 2 | 5.0 |
Hybridomas/*physiology | 2 | 100.0 |
T-Lymphocytes/*physiology | 4 | 1.0 |
Binding, Competitive/immunology | 2 | 2.0 |
Macromolecular Substances | 8 | 0.0 |
Antigens, CD19/*analysis | 10 | 83.0 |
Receptors, Antigen, T-Cell, gamma-delta/*analysis | 2 | 5.0 |
Antigens, CD19/*chemistry | 2 | 100.0 |
Leukemia, Lymphocytic, Acute, L1/*immunology | 2 | 33.0 |
Leukemia, Lymphocytic, Acute, L2/*immunology | 2 | 50.0 |
Immunoglobulin E/analysis | 3 | 5.0 |
Lymphocyte Subsets/pathology | 4 | 16.0 |
Tumor Markers, Biological | 4 | 0.0 |
Enzyme Activation/genetics/immunology | 2 | 10.0 |
Mice, Mutant Strains | 4 | 0.0 |
Leukemia, Myeloid/*genetics/immunology | 2 | 33.0 |
Oligonucleotide Probes | 2 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Whole-Body Irradiation | 3 | 3.0 |
Longitudinal Studies | 6 | 0.0 |
Lymphocyte Subsets/*drug effects/immunology | 2 | 22.0 |
Methotrexate/*therapeutic use | 4 | 16.0 |
B-Lymphocytes/immunology/*pathology | 7 | 26.0 |
Staining and Labeling/methods | 3 | 2.0 |
Antigens, CD13/*metabolism | 2 | 28.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Fetus/cytology/immunology | 2 | 33.0 |
Histocompatibility Antigens Class I/*metabolism | 2 | 2.0 |
Cytokines/*blood | 2 | 0.0 |
Surgical Procedures, Elective | 2 | 9.0 |
*Transplantation Chimera | 2 | 10.0 |
Cell Adhesion Molecules/immunology | 3 | 4.0 |
Granulocytes/immunology | 3 | 5.0 |
Leukocytes/*immunology | 8 | 5.0 |
Lymphocytes/immunology | 10 | 2.0 |
Bone Marrow Examination | 5 | 14.0 |
Predictive Value of Tests | 10 | 0.0 |
Immunoglobulin G/metabolism | 4 | 2.0 |
Antigens, CD19/chemistry/*metabolism | 2 | 100.0 |
Binding, Competitive | 3 | 0.0 |
Cell Line, Tumor | 9 | 0.0 |
Cytoplasm/*chemistry | 2 | 8.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Antigens, CD20/*metabolism | 2 | 22.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Blood Transfusion, Autologous | 2 | 8.0 |
Phospholipase C/metabolism | 2 | 0.0 |
Receptors, Antigen, B-Cell/*physiology | 10 | 13.0 |
Bronchial Provocation Tests | 2 | 2.0 |
Bronchoconstrictor Agents/diagnostic use | 2 | 28.0 |
Methacholine Chloride/diagnostic use | 2 | 11.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Ploidies | 2 | 0.0 |
Lymph Nodes/pathology | 9 | 3.0 |
Gene Expression/drug effects | 2 | 0.0 |
Point Mutation | 4 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Neprilysin/*analysis | 5 | 41.0 |
Macrophages/immunology | 4 | 1.0 |
Integrin alphaXbeta2/*analysis | 2 | 33.0 |
Apoptosis | 9 | 0.0 |
Blood Cells | 4 | 11.0 |
Bone Marrow Cells | 38 | 8.0 |
Hematopoietic Stem Cells/classification/*metabolism | 2 | 100.0 |
Stromal Cells/cytology | 3 | 6.0 |
HIV Infections/blood/*immunology | 2 | 3.0 |
HIV Seronegativity/immunology | 3 | 5.0 |
Proportional Hazards Models | 4 | 0.0 |
Receptors, Interleukin-2/metabolism | 6 | 3.0 |
Cell Membrane/immunology | 6 | 2.0 |
Cell Separation/methods | 6 | 3.0 |
Interferon Type II/secretion | 4 | 3.0 |
Interleukin-10/secretion | 2 | 6.0 |
Interleukin-4/secretion | 3 | 7.0 |
Leukocytes, Mononuclear/cytology/*immunology | 2 | 22.0 |
Leukocytes, Mononuclear/*immunology | 9 | 5.0 |
Periodontal Index | 4 | 8.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 2 | 4.0 |
*Killer Cells, Natural | 2 | 9.0 |
*T-Lymphocytes | 4 | 8.0 |
Antigens, CD/*immunology/*metabolism | 2 | 33.0 |
Apoptosis/*immunology | 3 | 1.0 |
Cell Lineage/immunology | 2 | 6.0 |
Phytohemagglutinins/pharmacology | 8 | 1.0 |
Antibodies, Bispecific/*immunology | 4 | 21.0 |
Membrane Glycoproteins/genetics/*metabolism | 2 | 1.0 |
Histocytochemistry | 14 | 2.0 |
Blast Crisis | 2 | 5.0 |
Bone Marrow/immunology/pathology | 7 | 19.0 |
Leukemia, B-Cell, Acute/*genetics/immunology/pathology | 2 | 100.0 |
DNA Replication | 3 | 0.0 |
Herpesvirus 4, Human/*physiology | 3 | 5.0 |
Receptors, Complement 3d/*physiology | 4 | 23.0 |
Virus Latency | 2 | 3.0 |
Antibodies, Monoclonal/diagnostic use | 40 | 4.0 |
Antigens, CD11/analysis | 2 | 6.0 |
Dental Plaque Index | 2 | 8.0 |
Killer Cells, Natural/drug effects/immunology | 3 | 9.0 |
Cats | 2 | 0.0 |
Evaluation Studies | 7 | 1.0 |
*Immunohistochemistry | 3 | 3.0 |
Neoplasm Proteins/*analysis | 6 | 1.0 |
Receptors, Immunologic/immunology | 3 | 2.0 |
Antigens, CD19/*physiology | 8 | 80.0 |
Enzyme Activation/immunology | 2 | 1.0 |
src Homology Domains/immunology | 2 | 7.0 |
Antigens, CD/*biosynthesis | 7 | 3.0 |
Drug Resistance, Multiple/genetics | 2 | 4.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Antigens, CD80/*biosynthesis | 2 | 5.0 |
B-Lymphocytes/immunology/metabolism | 2 | 3.0 |
Hyperplasia | 2 | 0.0 |
Antigens, CD/biosynthesis/blood | 2 | 22.0 |
Fetal Blood/immunology | 3 | 4.0 |
Fetus/*immunology | 2 | 4.0 |
Hematopoietic Stem Cells/immunology/pathology | 3 | 16.0 |
Hypercalcemia/*etiology | 2 | 18.0 |
*HIV-1 | 2 | 0.0 |
Killer Cells, Natural/metabolism | 4 | 7.0 |
DNA, Viral/analysis | 8 | 2.0 |
Antigens, CD/immunology/*metabolism | 3 | 6.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 22 | 6.0 |
Dendritic Cells/*pathology | 3 | 8.0 |
Leukemia/*pathology | 3 | 7.0 |
Lymphocytes/*drug effects/immunology | 2 | 8.0 |
Antigens, CD19/analysis/immunology | 3 | 100.0 |
Antigens, CD45/analysis/immunology | 2 | 33.0 |
B-Lymphocytes/chemistry/immunology | 2 | 25.0 |
CD4-Positive T-Lymphocytes/chemistry/immunology | 2 | 20.0 |
DNA, Complementary | 2 | 0.0 |
Lymphocyte Activation/*immunology | 10 | 2.0 |
Antibodies/pharmacology | 2 | 0.0 |
Membrane Glycoproteins/physiology | 3 | 1.0 |
Chromosomes, Human, Pair 21/*genetics | 3 | 3.0 |
Chromosomes, Human, Pair 8/*genetics | 3 | 2.0 |
Drug Synergism | 7 | 0.0 |
*Mitogen-Activated Protein Kinase Kinases | 2 | 2.0 |
Protein-Tyrosine Kinase/*metabolism | 4 | 0.0 |
Biopsy, Needle | 4 | 0.0 |
Thyroid Gland/*immunology | 2 | 3.0 |
Bone Marrow/embryology | 4 | 16.0 |
Liver/embryology | 2 | 6.0 |
Transplantation Chimera | 3 | 8.0 |
Injections, Subcutaneous | 4 | 1.0 |
Lymphocyte Count/drug effects | 5 | 13.0 |
Antigens, Neoplasm/*metabolism | 4 | 4.0 |
Apoptosis/immunology | 2 | 2.0 |
Immunoglobulins, Surface/immunology | 2 | 18.0 |
Leukemia, Myelocytic, Acute/*genetics/pathology | 2 | 6.0 |
Allergens/*immunology | 2 | 2.0 |
*Lymphocyte Subsets/immunology | 2 | 40.0 |
Antibodies, Monoclonal/*immunology | 20 | 2.0 |
Membrane Glycoproteins/*immunology | 2 | 1.0 |
Aging/*immunology | 6 | 5.0 |
Androstadienes/pharmacology | 3 | 1.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Morpholines/pharmacology | 2 | 0.0 |
Immunoglobulins, kappa-Chain/analysis | 4 | 19.0 |
Immunoglobulins, lambda-Chain/analysis | 3 | 18.0 |
Paraffin | 3 | 6.0 |
Antigens, CD19/genetics/metabolism | 2 | 66.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Immunoglobulins, Light-Chain/*genetics | 2 | 16.0 |
Receptors, IgE/*analysis | 2 | 22.0 |
Lymphocyte Subsets/*physiology | 2 | 18.0 |
Bone Marrow Cells/*metabolism | 2 | 4.0 |
DNA Nucleotidylexotransferase/*analysis | 3 | 30.0 |
Antigen-Antibody Reactions | 9 | 2.0 |
Blood Cell Count | 6 | 2.0 |
Microspheres | 6 | 3.0 |
*Endocytosis | 2 | 1.0 |
Protein Conformation | 4 | 0.0 |
Biological Response Modifiers/adverse effects/therapeutic use | 2 | 66.0 |
Receptors, Antigen, T-Cell, gamma-delta/analysis | 4 | 10.0 |
Tumor Stem Cells/pathology | 3 | 9.0 |
Antigens, CD19/drug effects | 2 | 100.0 |
Antigens, Surface/drug effects | 2 | 33.0 |
B-Lymphocytes/*drug effects | 2 | 10.0 |
Interleukin-6/biosynthesis | 3 | 1.0 |
Killer Cells, Natural/drug effects | 3 | 8.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
Mitogens/pharmacology | 5 | 1.0 |
T-Lymphocytes/*drug effects | 2 | 2.0 |
Autoantibodies/blood | 2 | 1.0 |
Thyroid Gland/immunology | 2 | 4.0 |
Burkitt Lymphoma | 4 | 4.0 |
Leukemia, Myeloid, Chronic | 2 | 8.0 |
Leukemia, Promyelocytic, Acute | 2 | 3.0 |
*Philadelphia Chromosome | 5 | 6.0 |
Tumor Cells, Cultured/drug effects | 6 | 1.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 4 | 2.0 |
Antigens, CD3/analysis/immunology | 3 | 25.0 |
HIV Seropositivity | 3 | 2.0 |
Fluorescent Antibody Technique, Direct | 5 | 4.0 |
Leukemia, Hairy Cell/immunology | 2 | 28.0 |
Leukemia, Lymphocytic, Chronic/immunology | 2 | 20.0 |
Lymphoma, B-Cell/immunology | 2 | 11.0 |
Dosage Compensation (Genetics) | 3 | 2.0 |
*Hematopoiesis | 3 | 1.0 |
Neutrophils/pathology | 4 | 6.0 |
Leukemia, Myeloid/*genetics/*immunology | 2 | 100.0 |
B-Lymphocytes/*immunology/metabolism | 5 | 10.0 |
Antigens, CD/analysis/*immunology | 4 | 10.0 |
Antigens, CD3/analysis/*immunology | 2 | 33.0 |
*Antibodies, Monoclonal | 8 | 3.0 |
Leukemia/therapy | 2 | 5.0 |
Interphase | 2 | 1.0 |
Retinoids/*pharmacology | 2 | 3.0 |
Growth Substances/pharmacology | 2 | 1.0 |
Immunotoxins/therapeutic use | 3 | 30.0 |
Antibodies, Monoclonal/chemistry | 3 | 3.0 |
Digitonin | 2 | 25.0 |
Fixatives | 2 | 2.0 |
Light | 4 | 1.0 |
Membrane Proteins/*analysis | 3 | 4.0 |
Receptors, Antigen, T-Cell/*analysis | 2 | 3.0 |
Scattering, Radiation | 5 | 4.0 |
Tissue Fixation/*methods | 3 | 20.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Antigens, CD11c/analysis | 3 | 30.0 |
Cytokines/pharmacology | 3 | 0.0 |
Glycophorin/analysis | 2 | 14.0 |
Antigens, CD19/immunology/*metabolism | 5 | 100.0 |
Biological Transport/immunology | 2 | 7.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Antigens, CD4/*immunology | 2 | 0.0 |
Cell Differentiation/immunology | 6 | 1.0 |
T-Lymphocytes/immunology/*pathology | 2 | 5.0 |
B-Lymphocytes/*immunology/*pathology | 3 | 75.0 |
Cell Adhesion Molecules/*immunology | 3 | 5.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
HIV Infections/*complications | 3 | 1.0 |
Herpesvirus 8, Human/genetics/*isolation & purification | 2 | 28.0 |
Chromosomes, Human, Pair 11 | 7 | 1.0 |
Spleen/pathology | 2 | 2.0 |
Leukemia/*immunology/pathology | 2 | 18.0 |
Aneuploidy | 5 | 2.0 |
Multiple Myeloma/*immunology | 7 | 18.0 |
Paraproteinemias/*immunology | 2 | 10.0 |
Plasma Cells/*immunology | 7 | 25.0 |
Psychoneuroimmunology | 2 | 13.0 |
B-Lymphocytes/*enzymology | 3 | 15.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 4 | 4.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 2 | 0.0 |
Nuclear Proteins/genetics/*physiology | 2 | 4.0 |
Leukemia/*diagnosis | 4 | 40.0 |
Nuclear Proteins/analysis | 3 | 1.0 |
Antigens, CD4/*analysis | 2 | 1.0 |
*Kidney Transplantation | 3 | 0.0 |
Lymphocytes/*immunology/pathology | 2 | 10.0 |
Genes, myc | 4 | 1.0 |
Hematopoietic Stem Cells/cytology/metabolism | 2 | 8.0 |
Interleukin-7/pharmacology | 3 | 6.0 |
Mutagenesis | 2 | 0.0 |
Receptors, Antigen, B-Cell/genetics | 2 | 40.0 |
Antigens, CD/*physiology | 12 | 3.0 |
*Cell Adhesion | 3 | 1.0 |
Leukemia, Lymphocytic, Acute, L1/*immunology/pathology | 3 | 60.0 |
HLA Antigens/analysis | 2 | 0.0 |
*Genes, p53 | 3 | 0.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
Macaca fascicularis | 2 | 0.0 |
HIV Infections/*immunology | 3 | 0.0 |
Bone Marrow Transplantation/*methods | 4 | 9.0 |
Protein Engineering | 2 | 2.0 |
B-Lymphocytes/*immunology/metabolism/pathology | 2 | 66.0 |
Multiple Myeloma/*immunology/pathology | 4 | 22.0 |
*DNA-Binding Proteins | 3 | 0.0 |
NF-kappa B/metabolism | 2 | 0.0 |
*B-Lymphocytes | 5 | 17.0 |
Glucocorticoids/therapeutic use | 2 | 2.0 |
Immunoglobulins, Surface/analysis | 10 | 21.0 |
Receptor Aggregation | 2 | 2.0 |
Receptors, IgG/*physiology | 3 | 10.0 |
Antigens, Surface/*physiology | 3 | 4.0 |
Lymphocytes/immunology/*physiology | 2 | 11.0 |
Cell Fractionation | 2 | 0.0 |
HLA-DR Antigens/analysis/blood | 2 | 100.0 |
Immune System/physiology | 2 | 8.0 |
Institutionalization | 2 | 28.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
Hematopoiesis/*drug effects | 5 | 5.0 |
Interleukin-4/*pharmacology | 9 | 4.0 |
Interleukin-7/*pharmacology | 4 | 9.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Cell Differentiation/physiology | 6 | 1.0 |
Interleukin-2/pharmacology | 16 | 2.0 |
Stimulation, Chemical | 4 | 0.0 |
Antigens, Differentiation, Myelomonocytic/blood | 3 | 18.0 |
Leukemia, Lymphocytic, Acute/genetics/*immunology/pathology | 2 | 66.0 |
Leukemia, Myelocytic, Acute/genetics/*immunology/pathology | 2 | 100.0 |
Antigens, CD34/immunology | 2 | 3.0 |
Neprilysin/immunology | 2 | 66.0 |
Receptors, Antigen, B-Cell/*immunology | 4 | 10.0 |
Histamine Release | 2 | 3.0 |
Cytokines/*immunology | 2 | 2.0 |
Interleukin-10/biosynthesis | 3 | 2.0 |
Receptors, Fc/metabolism | 2 | 4.0 |
Fluorometry | 2 | 2.0 |
HIV Seropositivity/immunology | 2 | 2.0 |
Romania | 3 | 17.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Staining and Labeling | 13 | 2.0 |
Herpesvirus 4, Human | 7 | 5.0 |
Linkage (Genetics) | 3 | 0.0 |
Bone Marrow Cells/cytology/*immunology | 2 | 15.0 |
Hospitalization | 2 | 1.0 |
Exercise/*physiology | 4 | 1.0 |
Leukocytes/*physiology | 2 | 3.0 |
Norepinephrine/blood | 2 | 1.0 |
Crosses, Genetic | 4 | 0.0 |
Immune Tolerance/*immunology | 2 | 4.0 |
Receptors, Complement 3d/immunology | 3 | 16.0 |
Signal Transduction/*physiology | 5 | 0.0 |
Calcium/*physiology | 3 | 2.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 3 | 1.0 |
Antigens, CD14/immunology | 3 | 5.0 |
Antigens, CD45/immunology | 2 | 3.0 |
Leukocyte Count/*methods | 2 | 25.0 |
Cell Adhesion Molecules/*metabolism | 3 | 1.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Interleukin-7/*metabolism | 2 | 28.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 2 | 0.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Antigens, CD20/immunology | 5 | 35.0 |
Cytokines/metabolism | 2 | 0.0 |
Herpesvirus 4, Human/isolation & purification | 4 | 6.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain/*genetics | 2 | 40.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/*genetics | 3 | 33.0 |
Lymphokines/*secretion | 2 | 4.0 |
Tumor Necrosis Factor-alpha/secretion | 4 | 3.0 |
Antibodies/*pharmacology | 2 | 6.0 |
Lymphocyte Subsets/drug effects/*immunology | 3 | 60.0 |
Regeneration | 2 | 3.0 |
*Antigens, Differentiation, B-Lymphocyte | 3 | 20.0 |
Leukemia, Lymphocytic, Acute/*therapy | 2 | 12.0 |
Antigens, CD95/*immunology | 2 | 5.0 |
Leukocytes, Mononuclear/*virology | 2 | 5.0 |
*Gene Rearrangement, B-Lymphocyte | 2 | 7.0 |
Immunoglobulins, Heavy-Chain/*genetics/immunology | 2 | 28.0 |
Monocytes/metabolism | 3 | 0.0 |
Autoimmune Diseases/*immunology | 2 | 1.0 |
Interferon Type II/metabolism | 2 | 0.0 |
Interleukin-2/metabolism | 2 | 1.0 |
Killer Cells, Lymphokine-Activated/*drug effects/immunology | 2 | 33.0 |
Superoxides/metabolism | 2 | 0.0 |
Structure-Activity Relationship | 5 | 0.0 |
Receptors, Antigen, T-Cell/analysis | 10 | 9.0 |
Smoking/*immunology | 2 | 20.0 |
Blast Crisis/*pathology | 2 | 11.0 |
Chromosomes, Human, Pair 9 | 5 | 3.0 |
Fusion Proteins, bcr-abl/*genetics | 3 | 3.0 |
Leukemia, Myelocytic, Acute/*pathology | 2 | 5.0 |
Leukemia, Myeloid, | 2 | 100.0 |
Antigens, Differentiation/immunology | 3 | 2.0 |
Periodic Acid-Schiff Reaction | 3 | 11.0 |
Chromosome Aberrations/*genetics/pathology | 2 | 50.0 |
Chromosomes, Human, Pair 18 | 4 | 3.0 |
Prednisolone/therapeutic use | 2 | 2.0 |
Blast Crisis/immunology/pathology | 2 | 40.0 |
Mice, Inbred Strains | 3 | 0.0 |
Lymph Nodes/cytology | 2 | 4.0 |
Macrophages/*physiology | 2 | 2.0 |
*Bone Marrow Cells | 26 | 10.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Immunoglobulins, mu-Chain/metabolism | 3 | 50.0 |
Anthropometry | 2 | 0.0 |
Antigens, CD19/*genetics/metabolism | 2 | 100.0 |
Electrophoresis, Polyacrylamide Gel | 9 | 0.0 |
Tonsil | 2 | 9.0 |
Bone Marrow/embryology/immunology | 3 | 60.0 |
Fetus | 3 | 0.0 |
Gestational Age | 2 | 0.0 |
Integrin alphaXbeta2/analysis | 2 | 13.0 |
Clone Cells/immunology | 4 | 2.0 |
Immunoglobulins, Light-Chain/immunology | 2 | 25.0 |
Fluoresceins | 2 | 3.0 |
Killer Cells, Natural/*metabolism | 2 | 3.0 |
1-Phosphatidylinositol 3-Kinase | 8 | 5.0 |
Probability | 2 | 0.0 |
Sampling Studies | 2 | 1.0 |
Agammaglobulinemia/*immunology | 2 | 16.0 |
*Cell Differentiation | 3 | 1.0 |
Killer Cells, Natural/pathology | 2 | 6.0 |
T-Lymphocytes, Helper-Inducer/pathology | 4 | 12.0 |
DNA, Neoplasm/genetics | 7 | 0.0 |
Calcium/physiology | 4 | 1.0 |
Germinal Center/cytology | 2 | 25.0 |
Viral Matrix Proteins/*analysis | 2 | 25.0 |
Immunization/*methods | 2 | 25.0 |
Infant, Newborn/*immunology | 2 | 8.0 |
Isoantibodies/*immunology | 2 | 5.0 |
Immunoglobulin G/biosynthesis | 4 | 2.0 |
Antigens, CD/*analysis/immunology | 4 | 13.0 |
Antigens, Surface/*analysis/immunology | 3 | 16.0 |
Calcimycin/pharmacology | 2 | 0.0 |
Centrifugation, Density Gradient | 4 | 1.0 |
Histamine Release/drug effects | 2 | 8.0 |
Multiple Myeloma/*blood | 2 | 8.0 |
Plasma Cells/*pathology | 4 | 21.0 |
Autoradiography | 2 | 0.0 |
Tyrosine/*metabolism | 2 | 0.0 |
Autoantibodies/*immunology | 3 | 1.0 |
Immunoglobulins, kappa-Chain/*immunology | 2 | 40.0 |
Immunoglobulins, lambda-Chain/*immunology | 2 | 66.0 |
Immunologic Capping | 3 | 6.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Receptors, Antigen, B-Cell/immunology | 2 | 8.0 |
Chromosomes, Human, Pair 17 | 2 | 0.0 |
Genes, abl | 3 | 8.0 |
T-Lymphocyte Subsets | 4 | 3.0 |
*Blood Donors | 6 | 5.0 |
Immunoglobulin Variable Region/*genetics | 4 | 3.0 |
Leukemia, B-Cell, Chronic/*genetics/immunology | 2 | 50.0 |
*Gene Expression Regulation, Leukemic | 3 | 3.0 |
G1 Phase | 2 | 0.0 |
Leukemia, Lymphocytic, Acute/*genetics/*immunology | 2 | 100.0 |
Liver/cytology/*embryology | 2 | 20.0 |
Radiation Chimera | 3 | 6.0 |
*Dental Implants | 2 | 25.0 |
Neutrophils/enzymology | 2 | 2.0 |
Antigens, CD40/*immunology | 2 | 5.0 |
Concanavalin A/pharmacology | 2 | 0.0 |
HLA-DR Antigens/analysis/immunology | 3 | 15.0 |
Pokeweed Mitogens/pharmacology | 6 | 7.0 |
Receptors, Interleukin-2/analysis/immunology | 2 | 33.0 |
Cell Differentiation/genetics | 2 | 0.0 |
DNA Nucleotidylexotransferase/analysis | 5 | 25.0 |
*Lymphocyte Activation/genetics | 2 | 7.0 |
Receptors, Interleukin-7 | 2 | 11.0 |
Bone Marrow/immunology | 14 | 11.0 |
Lymphoma, B-Cell/immunology/pathology | 2 | 20.0 |
Plasma Cells/*immunology/metabolism | 2 | 100.0 |
*Cell Transformation, Viral | 4 | 2.0 |
Leukemia, Myeloid, Chronic/*immunology/*pathology | 2 | 100.0 |
Hodgkin Disease/immunology/pathology | 2 | 33.0 |
Lung/immunology/pathology | 2 | 8.0 |
Lymphoma, Non-Hodgkin/immunology/pathology | 2 | 20.0 |
Culture Techniques | 3 | 0.0 |
Receptors, Transferrin/analysis | 4 | 11.0 |
Cell Adhesion Molecules/*biosynthesis | 2 | 2.0 |
Bleomycin/administration & dosage | 2 | 2.0 |
Etoposide/administration & dosage | 3 | 2.0 |
Leucovorin/administration & dosage | 2 | 6.0 |
Graft Rejection/*immunology | 2 | 2.0 |
Immunoglobulin G/*analysis | 2 | 2.0 |
Monocytes/*immunology | 2 | 0.0 |
Antigens, Differentiation | 5 | 6.0 |
*Hematopoietic Stem Cells | 2 | 4.0 |
*Homeodomain Proteins | 4 | 1.0 |
Protein Biosynthesis | 3 | 0.0 |
False Negative Reactions | 2 | 1.0 |
False Positive Reactions | 3 | 1.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Antibiotics, Antineoplastic/therapeutic use | 2 | 11.0 |
Doxorubicin/therapeutic use | 2 | 3.0 |
Epitopes | 4 | 0.0 |
Immunotherapy/*methods | 3 | 2.0 |
Vincristine/therapeutic use | 3 | 7.0 |
*Aneuploidy | 3 | 3.0 |
B-Lymphocytes/*chemistry | 4 | 19.0 |
Hematopoietic Stem Cells/*chemistry | 5 | 18.0 |
Cold | 2 | 1.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
N-Glycosyl Hydrolases/analysis | 3 | 11.0 |
Burkitt Lymphoma/pathology | 4 | 12.0 |
Macrophage-1 Antigen/analysis | 2 | 4.0 |
Antigens, CD20/immunology/metabolism | 2 | 100.0 |
Butyric Acid | 3 | 6.0 |
Butyric Acids/pharmacology | 2 | 6.0 |
Stem Cells | 2 | 1.0 |
Acute-Phase Reaction | 2 | 4.0 |
Recombinant Proteins/therapeutic use | 5 | 1.0 |
Tetrachlorodibenzodioxin/*toxicity | 2 | 4.0 |
T-Lymphocytes, Cytotoxic/*immunology | 6 | 1.0 |
Blood Cells/*immunology | 3 | 15.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Cell Cycle/drug effects | 2 | 0.0 |
*Herpesvirus 4, Human | 4 | 11.0 |
Tretinoin/pharmacology | 2 | 0.0 |
Hodgkin Disease/*metabolism | 2 | 20.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
DNA-Binding Proteins/analysis/genetics | 2 | 11.0 |
Models, Immunological | 3 | 1.0 |
Lymphoma, B-Cell/pathology | 2 | 10.0 |
Hematopoietic Stem Cells/*cytology/*immunology | 2 | 8.0 |
Substrate Specificity | 2 | 0.0 |
Epitopes/*immunology | 2 | 0.0 |
*Bone Marrow Purging | 3 | 12.0 |
*Immunomagnetic Separation | 3 | 16.0 |
Antigens, Surface/blood | 3 | 13.0 |
Fixatives/*pharmacology | 2 | 28.0 |
B-Lymphocytes/*immunology/physiology | 4 | 36.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
*Age Factors | 2 | 25.0 |
Lipopolysaccharides/immunology | 3 | 2.0 |
Filgrastim/pharmacology | 2 | 20.0 |
Hematopoietic Cell Growth Factors/pharmacology | 5 | 6.0 |
Transplantation Conditioning | 3 | 5.0 |
Tumor Stem Cell Assay | 5 | 2.0 |
Antigens, CD/analysis/*biosynthesis | 2 | 7.0 |
Gene Rearrangement, T-Lymphocyte | 6 | 5.0 |
Immunoglobulins, Fab/immunology | 6 | 5.0 |
DNA Probes | 6 | 0.0 |
Antigens, Neoplasm/*analysis | 20 | 5.0 |
Gene Rearrangement, B-Lymphocyte, Light Chain | 6 | 27.0 |
Leukemia, Pre-B-Cell/*pathology | 2 | 33.0 |
Respiratory Burst | 2 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 2 | 1.0 |
Leukemia, Lymphocytic, Acute/immunology/*pathology | 2 | 22.0 |
Antigens, Surface/metabolism | 5 | 4.0 |
DNA Nucleotidylexotransferase/*metabolism | 3 | 50.0 |
Gene Expression Regulation, Leukemic | 4 | 4.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 2 | 2.0 |
Histocompatibility Testing/*methods | 2 | 1.0 |
Cytokines/analysis | 2 | 2.0 |
Lymphocyte Subsets/immunology/*metabolism | 2 | 28.0 |
Antigens, Differentiation, B-Lymphocyte/*physiology | 10 | 28.0 |
Immunoglobulin M/analysis | 4 | 1.0 |
Immunoglobulins, Light-Chain/analysis | 2 | 15.0 |
Japan/epidemiology | 2 | 0.0 |
Splenomegaly/etiology | 2 | 11.0 |
Antigens, CD40/*metabolism | 2 | 4.0 |
Immunoglobulin M/*metabolism | 3 | 8.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Membrane Proteins/*metabolism | 3 | 0.0 |
N-Glycosyl Hydrolases/biosynthesis | 2 | 28.0 |
Carboxylic Ester Hydrolases/metabolism | 2 | 10.0 |
Viral Matrix Proteins/analysis | 2 | 14.0 |
Phagocytosis/*immunology | 2 | 3.0 |
*Chromosome Disorders | 3 | 4.0 |
*Gene Rearrangement, B-Lymphocyte, Heavy Chain | 3 | 14.0 |
Complement 3d | 2 | 2.0 |
Human T-lymphotropic virus 1 | 2 | 15.0 |
Blood Component Removal | 3 | 6.0 |
Cytoplasm/immunology | 10 | 10.0 |
DNA Primers/chemistry | 4 | 0.0 |
Gamma Rays | 2 | 0.0 |
Hematopoietic Stem Cells/*cytology | 6 | 2.0 |
Plasma Cells/*cytology | 2 | 66.0 |
Lymphoma, B-Cell/*pathology | 2 | 8.0 |
Killer Cells, Natural/immunology/metabolism | 2 | 6.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Colitis, Ulcerative/*immunology | 3 | 8.0 |
Breast Neoplasms/*immunology/pathology | 2 | 8.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 2 | 2.0 |
Leukemia, Lymphocytic/genetics/immunology/*pathology | 2 | 50.0 |
Receptors, Antigen, T-Cell/genetics | 3 | 3.0 |
*Leukocyte Count | 2 | 3.0 |
Chromosomes, Human, Pair 21/*ultrastructure | 3 | 50.0 |
Chromosomes, Human, Pair 8/*ultrastructure | 3 | 42.0 |
Antigens, CD8/immunology | 2 | 2.0 |
Treponema pallidum/*immunology | 2 | 25.0 |
*Genes, myc | 4 | 1.0 |
Interferon-alpha/*biosynthesis | 2 | 11.0 |
Leukocytes, Mononuclear/*metabolism | 2 | 1.0 |
Etoposide/pharmacology | 2 | 1.0 |
Growth Hormone/*deficiency | 2 | 6.0 |
Killer Cells, Natural/*pathology | 3 | 10.0 |
Antigens, Differentiation, B-Lymphocyte/*biosynthesis | 2 | 22.0 |
B-Lymphocytes/drug effects/*immunology | 6 | 18.0 |
Tonsil/cytology | 3 | 3.0 |
Proto-Oncogene Proteins/isolation & purification | 2 | 40.0 |
Proto-Oncogene Proteins c-bcl-2 | 7 | 4.0 |
Immunoglobulins/biosynthesis | 5 | 4.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
Cell Adhesion Molecules/analysis | 5 | 3.0 |
Antigens, Differentiation, Myelomonocytic | 2 | 7.0 |
T-Lymphocytes/physiology | 4 | 3.0 |
Immunity, Cellular/*drug effects | 2 | 4.0 |
Lymphocyte Subsets/drug effects | 3 | 15.0 |
Interleukin-2/*biosynthesis | 3 | 2.0 |
T-Lymphocytes/immunology/*physiology | 2 | 3.0 |
Hematopoietic Stem Cells/drug effects | 2 | 3.0 |
Peanut Agglutinin | 3 | 10.0 |
Antigens, CD3/genetics | 3 | 21.0 |
ADP-ribosyl Cyclase/*metabolism | 3 | 15.0 |
Immunoglobulin G/*metabolism | 2 | 3.0 |
Receptors, Interleukin-2/immunology | 2 | 3.0 |
Gelatin | 2 | 13.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 2 | 3.0 |
Thymidine/metabolism | 2 | 0.0 |
Continental Population Groups | 3 | 1.0 |
Ethnic Groups | 3 | 1.0 |
Malaysia | 2 | 5.0 |
DNA Nucleotidylexotransferase/metabolism | 4 | 21.0 |
Acid Phosphatase/metabolism | 2 | 3.0 |
Antigens, CD/immunology/*physiology | 2 | 6.0 |
Enzyme Inhibitors/therapeutic use | 2 | 2.0 |
B-Lymphocytes/*classification | 2 | 40.0 |
Peroxidase/*metabolism | 4 | 6.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 2 | 4.0 |
Epitopes/immunology | 2 | 0.0 |
Leukemia, B-Cell/immunology/*therapy | 2 | 66.0 |
Phosphotyrosine | 2 | 0.0 |
Tyrosine/analogs & derivatives/metabolism | 2 | 1.0 |
*Chromosome Deletion | 2 | 0.0 |
Leukemia, Nonlymphocytic, Acute/*genetics | 3 | 37.0 |
Lymphocyte Depletion | 5 | 3.0 |
*Chromosomes, Human, Pair 4 | 5 | 2.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
*Gene Rearrangement, T-Lymphocyte | 5 | 10.0 |
Alkaline Phosphatase/*immunology | 2 | 66.0 |
Antigens, CD5 | 19 | 7.0 |
Herpesvirus 4, Human/genetics | 3 | 4.0 |
Proto-Oncogenes | 2 | 1.0 |
Bone Marrow/metabolism | 3 | 2.0 |
Temperature | 3 | 0.0 |
Acyclovir/therapeutic use | 2 | 18.0 |
ADP-ribosyl Cyclase/analysis | 4 | 19.0 |
Genes, Immunoglobulin/genetics | 4 | 16.0 |
Immunoglobulins/*biosynthesis | 3 | 6.0 |
*Asian Continental Ancestry Group | 2 | 3.0 |
*European Continental Ancestry Group | 2 | 2.0 |
Lymphocyte Subsets/*chemistry | 2 | 40.0 |
Lymphocyte Activation/drug effects/immunology | 2 | 3.0 |
Interleukin-2/*pharmacology | 3 | 1.0 |
Antibodies, Monoclonal/immunology/metabolism | 2 | 4.0 |
HLA-DR Antigens/*analysis | 7 | 4.0 |
*Phenotype | 2 | 0.0 |
Trypanosoma cruzi/*immunology | 2 | 9.0 |
Neutrophils/metabolism | 2 | 1.0 |
Cyclophosphamide/therapeutic use | 4 | 4.0 |
Methotrexate/therapeutic use | 2 | 3.0 |
Antigens, CD20 | 21 | 29.0 |
Antigens, CD/*immunology/metabolism | 4 | 12.0 |
Antigens, Differentiation, B-Lymphocyte/*immunology/metabolism | 3 | 37.0 |
Periodontitis/*immunology | 2 | 11.0 |
Proto-Oncogene Protein c-kit | 4 | 5.0 |
Receptors, Colony-Stimulating Factor/metabolism | 2 | 22.0 |
Receptors, Interleukin/metabolism | 2 | 3.0 |
Stem Cell Factor | 4 | 4.0 |
Antigens, Surface/immunology/metabolism | 2 | 14.0 |
Cytarabine/administration & dosage | 5 | 5.0 |
Daunorubicin/administration & dosage | 3 | 8.0 |
Blast Crisis/genetics/*pathology | 3 | 42.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Leukemia, Myeloid, Philadelphia-Positive/genetics/*pathology | 2 | 22.0 |
Immunoglobulins, Intravenous/therapeutic use | 2 | 5.0 |
Cell Adhesion/immunology | 6 | 3.0 |
Lymphocyte Function-Associated Antigen-1/physiology | 2 | 4.0 |
Cytological Techniques | 2 | 5.0 |
L-Selectin | 2 | 3.0 |
Interleukin-2/secretion | 2 | 2.0 |
CD4-Positive T-Lymphocytes/*cytology | 2 | 4.0 |
Aging/blood | 2 | 3.0 |
Lymphocyte Subsets/*cytology/immunology | 2 | 28.0 |
Bone Marrow/*immunology/pathology | 3 | 16.0 |
Immunoglobulins/*immunology | 2 | 7.0 |
Immunohistochemistry/*methods | 3 | 3.0 |
Antigens, CD30/analysis | 2 | 5.0 |
Recombinant Proteins | 4 | 0.0 |
*Pregnancy Complications, Infectious | 2 | 7.0 |
*T-Lymphocyte Subsets/immunology | 2 | 14.0 |
Burkitt Lymphoma/*immunology | 3 | 15.0 |
Immunotoxins | 2 | 22.0 |
Leukemia, B-Cell, Acute/*immunology | 4 | 66.0 |
Ricin/immunology | 2 | 50.0 |
Antigens, CD/*genetics | 3 | 1.0 |
Leukemia/*genetics/pathology | 2 | 11.0 |
Complement/metabolism | 2 | 2.0 |
Bone Marrow/immunology/*pathology | 4 | 23.0 |
Immunoglobulins/*blood | 2 | 6.0 |
Mitogens | 2 | 2.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis/immunology | 4 | 44.0 |
Antigens, CD57 | 3 | 4.0 |
Leukocyte Count/*drug effects | 2 | 22.0 |
Lymphocyte Count/*drug effects | 2 | 28.0 |
Immunoglobulin A/biosynthesis | 2 | 7.0 |
Receptors, Interleukin-6 | 4 | 4.0 |
Cell Adhesion Molecules/*blood | 3 | 5.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 3 | 7.0 |
Cell Aggregation/immunology | 3 | 15.0 |
Protein-Tyrosine Kinase/physiology | 2 | 1.0 |
Hematopoiesis/drug effects | 3 | 3.0 |
Culture Media, Conditioned | 2 | 0.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Antigens, CD40 | 7 | 12.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Antigens, Differentiation/*metabolism | 7 | 5.0 |
Ki-67 Antigen | 3 | 1.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Hybridomas | 2 | 1.0 |
RNA, Neoplasm/*analysis | 2 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis/*immunology | 2 | 40.0 |
Antigens, CD/*analysis/blood | 2 | 14.0 |
Immunosuppression | 2 | 1.0 |
Paraffin Embedding | 2 | 0.0 |
Antigens, CD14 | 6 | 2.0 |
*Mutation | 4 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis/*immunology | 2 | 33.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
Lymphokines/pharmacology | 2 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/analysis/immunology | 6 | 60.0 |
Leukemia, B-Cell/genetics/immunology/*pathology | 2 | 100.0 |
Cell Adhesion Molecules/biosynthesis | 2 | 2.0 |
Intercellular Adhesion Molecule-1 | 9 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/physiology | 3 | 15.0 |
Receptors, Antigen, T-Cell/*physiology | 2 | 1.0 |
Leukemia, T-Cell, Acute/diagnosis/*immunology/pathology | 2 | 100.0 |
Lymphocyte Subsets/immunology/*pathology | 3 | 23.0 |
Myelodysplastic Syndromes/*immunology | 2 | 40.0 |
T-Lymphocytes/cytology | 2 | 2.0 |
Antigens, CD7 | 7 | 6.0 |
Stem Cell Transplantation | 2 | 4.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Restriction Mapping | 3 | 0.0 |
Antigens, Surface/physiology | 2 | 5.0 |
Histocompatibility Antigens Class II/*physiology | 2 | 9.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
*Monosomy | 3 | 9.0 |
Complement | 2 | 4.0 |
Proto-Oncogene Proteins/*analysis | 3 | 1.0 |
Membrane Glycoproteins/*blood/genetics | 2 | 66.0 |
Drug Resistance/*genetics | 2 | 4.0 |
*Gene Expression | 2 | 0.0 |
P-Glycoprotein | 4 | 8.0 |
Leukemia, Lymphocytic, Acute/*immunology | 5 | 18.0 |
Lymphoma, Non-Hodgkin/pathology | 2 | 14.0 |
Membrane Glycoproteins/*physiology | 2 | 0.0 |
Receptors, Interleukin-2/*biosynthesis | 2 | 5.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 3 | 2.0 |
Antigens, CD29 | 2 | 3.0 |
Phytohemagglutinins | 2 | 2.0 |
Immunoglobulins, Surface/*analysis | 4 | 50.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 3 | 3.0 |
T-Lymphocytes, Suppressor-Effector/physiology | 2 | 16.0 |
Hepatitis B Core Antigens/*blood | 2 | 100.0 |
Hepatitis B Surface Antigens/*blood | 2 | 22.0 |
Lymphoid Tissue/*pathology | 2 | 14.0 |
Rosette Formation | 6 | 1.0 |
*Antigens, Neoplasm | 3 | 1.0 |
*Blast Crisis | 2 | 28.0 |
Antibodies, Monoclonal/biosynthesis | 2 | 7.0 |
Interleukin-6/*blood | 2 | 0.0 |
Autoimmune Diseases/immunology | 2 | 2.0 |
Immunologic Techniques | 3 | 0.0 |
Regression Analysis | 5 | 0.0 |
*Blood Cells | 2 | 50.0 |
Leukemia, B-Cell, Chronic/*immunology/pathology | 2 | 12.0 |
*Tissue Donors | 2 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/*genetics | 2 | 9.0 |
Hybrid Cells | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Antigens, CD13 | 6 | 11.0 |
Interleukin-3/metabolism | 2 | 6.0 |
B-Lymphocytes/classification/immunology | 2 | 33.0 |
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use | 2 | 4.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Genes, Immunoglobulin/*genetics | 2 | 4.0 |
Lymphoma, B-Cell/diagnosis | 2 | 66.0 |
Erythrocytes/immunology | 2 | 0.0 |
Cyclophosphamide/analogs & derivatives | 2 | 50.0 |
Receptors, Interleukin-2/*analysis | 3 | 4.0 |
Chromosome Fragility | 3 | 5.0 |
Multigene Family | 2 | 0.0 |
Recombinant Fusion Proteins/immunology | 2 | 1.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Peroxidase/*analysis | 3 | 15.0 |
Antigens, CD11 | 5 | 6.0 |
Antigens, Differentiation/*physiology | 2 | 2.0 |
Endocytosis | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 4 | 2.0 |
Risk Assessment | 2 | 0.0 |
Interleukin-3/*pharmacology | 4 | 3.0 |
Interleukin-6/*pharmacology | 4 | 1.0 |
Antigens, CD8/*analysis | 2 | 2.0 |
Lymphocyte Subsets/*pathology | 2 | 20.0 |
Antibodies, Anti-Idiotypic/blood | 2 | 14.0 |
Receptors, Immunologic/analysis | 6 | 6.0 |
Myasthenia Gravis/*immunology | 2 | 8.0 |
Thymus Gland/*immunology/pathology | 2 | 22.0 |
Leukemia/genetics/*pathology | 2 | 28.0 |
Chromosome Aberrations/pathology | 2 | 22.0 |
Radiation Dosage | 2 | 2.0 |
Lymphoma/immunology | 2 | 6.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/immunology | 3 | 23.0 |
Antigens, Viral/analysis | 2 | 2.0 |
Receptors, Immunologic/physiology | 2 | 1.0 |
Hematopoietic Stem Cells/cytology/*pathology | 2 | 66.0 |
Multiple Myeloma/*pathology | 5 | 8.0 |
Purpura, Thrombocytopenic, Idiopathic/pathology | 2 | 50.0 |
Receptors, Very Late Antigen/analysis | 2 | 25.0 |
Phosphatidylinositols/metabolism | 2 | 1.0 |
Skin/immunology | 2 | 2.0 |
T-Lymphocyte Subsets/*pathology | 2 | 6.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
Antigens, CD18 | 3 | 3.0 |
Neutrophils/*immunology | 3 | 1.0 |
Up-Regulation/immunology | 2 | 1.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 2 | 1.0 |
Drug Resistance | 2 | 0.0 |
Leukemia, Lymphocytic, Acute/*drug therapy | 2 | 14.0 |
Korea/epidemiology | 2 | 3.0 |
Receptors, Complement/analysis | 3 | 5.0 |
Leukemia, Lymphocytic, Chronic/metabolism/*pathology | 2 | 33.0 |
Antigens, CD30 | 2 | 7.0 |
Immunohistochemistry/methods | 5 | 0.0 |
Leukemia, Lymphocytic, Acute/*drug therapy/pathology | 2 | 50.0 |
*Cell Separation | 2 | 14.0 |
Dipeptides/pharmacology | 2 | 4.0 |
HLA-D Antigens/analysis | 3 | 5.0 |
Leukemia, Myeloid/*immunology | 2 | 5.0 |
Receptors, Complement 3d/*metabolism | 2 | 10.0 |
Cell Fusion | 2 | 0.0 |
Frozen Sections | 2 | 2.0 |
Epstein-Barr Virus Nuclear Antigens | 2 | 4.0 |
Leukemia/*immunology | 2 | 5.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Antibody-Dependent Cell Cytotoxicity | 4 | 4.0 |
Interleukin-6/secretion | 2 | 3.0 |
*Magnetics | 3 | 12.0 |
Magnetics | 9 | 11.0 |
Paraproteinemias/immunology | 3 | 33.0 |
Lymphoma, Non-Hodgkin/*genetics/pathology | 2 | 14.0 |
Leukemia, Lymphocytic, Chronic/*blood | 2 | 40.0 |
Leukemia, B-Cell, Chronic/genetics/immunology/*pathology | 2 | 40.0 |
B-Lymphocytes/*drug effects/immunology | 5 | 17.0 |
Hematopoietic Stem Cells/pathology | 2 | 5.0 |
Antigens, CD/analysis/*genetics | 2 | 13.0 |
Antigens, CD15 | 3 | 10.0 |
Antigens, Differentiation, B-Lymphocyte/analysis/*genetics | 2 | 100.0 |
Gene Expression/*genetics | 2 | 1.0 |
*Oncogenes | 2 | 0.0 |
DNA/biosynthesis | 4 | 0.0 |
*N-Glycosyl Hydrolases | 4 | 7.0 |
Immunoglobulins/genetics | 2 | 5.0 |
Immunoglobulins, kappa-Chain/*analysis | 2 | 22.0 |
Multiple Myeloma/blood/*immunology | 2 | 22.0 |
Receptors, Fc/analysis | 6 | 10.0 |
Receptors, IgE | 4 | 6.0 |
B-Lymphocyte Subsets/*immunology/pathology | 2 | 66.0 |
Lymph Nodes/immunology/pathology | 3 | 7.0 |
Lymphoma, AIDS-Related/*immunology/pathology | 2 | 50.0 |
Lymphoma, Large-Cell/etiology/*immunology/pathology | 2 | 100.0 |
Lymphoma, Non-Hodgkin/etiology/*immunology/pathology | 2 | 100.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
Platelet Count | 2 | 0.0 |
Neprilysin | 18 | 24.0 |
Antigens, Differentiation, T-Lymphocyte | 5 | 1.0 |
Receptors, Complement 3d | 6 | 4.0 |
Phorbol Esters/pharmacology | 3 | 2.0 |
Histocompatibility Antigens/*analysis | 2 | 4.0 |
*Antigens, Differentiation | 2 | 2.0 |
Leukocytes/cytology/*immunology | 2 | 33.0 |
HLA-DR Antigens | 2 | 0.0 |
Lymphoma, Non-Hodgkin/*diagnosis | 2 | 66.0 |
Leukemia, Lymphocytic, Acute/genetics/immunology/*pathology | 2 | 66.0 |
Histocompatibility Antigens/*analysis/genetics | 2 | 66.0 |
Lymphocyte Function-Associated Antigen-1/*physiology | 2 | 4.0 |
Receptors, Complement/*physiology | 2 | 3.0 |
HLA Antigens/immunology | 2 | 1.0 |
*Peripheral Blood Stem Cell Transplantation | 2 | 11.0 |
Gingival Hemorrhage/pathology | 2 | 50.0 |
Immunoglobulin A/analysis | 3 | 1.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Bone Marrow/immunology/*physiology | 2 | 50.0 |
Hematopoietic Stem Cells/immunology | 9 | 11.0 |
DNA/genetics | 4 | 0.0 |
Acquired Immunodeficiency Syndrome/complications/*immunology | 2 | 8.0 |
Sarcoma, Kaposi/etiology/*immunology | 2 | 66.0 |
Gene Deletion | 2 | 0.0 |
Antigens, CD8 | 6 | 2.0 |
Antigens, CD26 | 2 | 7.0 |
CD4-Positive T-Lymphocytes/cytology | 2 | 2.0 |
Immunologic Deficiency Syndromes/*immunology | 2 | 5.0 |
Interferon-gamma, Recombinant/*pharmacology | 3 | 2.0 |
Histocompatibility Antigens/analysis | 2 | 3.0 |
Antigens, Neoplasm/metabolism | 3 | 4.0 |
Histocytochemistry/methods | 2 | 11.0 |
Microscopy, Electron/methods | 2 | 3.0 |
Tumor Markers, Biological/*analysis/blood | 2 | 10.0 |
*Microspheres | 2 | 15.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 2 | 2.0 |
Receptors, Fc/biosynthesis | 2 | 12.0 |
*Multigene Family | 2 | 0.0 |
Leukemia, Lymphocytic, Chronic/*immunology/pathology | 2 | 66.0 |
Gene Rearrangement/*genetics | 2 | 5.0 |
Biological Markers/*blood | 2 | 1.0 |
Antigens, Surface/analysis/*immunology | 2 | 16.0 |
Antigens, Differentiation/*immunology | 3 | 2.0 |
Histocompatibility Antigens/*immunology | 2 | 8.0 |
Antigens, Differentiation, Myelomonocytic/*metabolism | 2 | 3.0 |
Antibodies, Monoclonal/diagnostic use/immunology | 2 | 7.0 |
T-Lymphocytes/drug effects | 2 | 3.0 |
Lymphocytes/*immunology/metabolism | 2 | 9.0 |
Cell Membrane/chemistry/immunology/ultrastructure | 2 | 100.0 |
United States | 2 | 0.0 |
B-Lymphocytes/*analysis | 3 | 21.0 |
Lymphoma/*immunology | 4 | 12.0 |
Lymphocyte Function-Associated Antigen-1 | 2 | 2.0 |
Tumor Markers, Biological/immunology | 2 | 11.0 |
B-Lymphocytes/cytology/immunology | 2 | 6.0 |
Burkitt Lymphoma/immunology/*pathology | 2 | 28.0 |
Leukemia, Myelocytic, Acute/genetics | 2 | 6.0 |
Complement/*immunology | 2 | 1.0 |
Plastics | 2 | 6.0 |
Stem Cell Transplantation/*methods | 2 | 11.0 |
Antibodies, Anti-Idiotypic/immunology | 2 | 5.0 |
Tumor Stem Cells/immunology | 2 | 15.0 |
B-Lymphocytes/classification/*immunology/pathology | 2 | 66.0 |
Interleukin-4 | 3 | 3.0 |
*Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 7.0 |
*Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 16.0 |
Interleukins/pharmacology | 3 | 4.0 |
Immune System/*radiation effects | 2 | 50.0 |
Lectins/metabolism | 2 | 2.0 |
DNA, Viral/blood | 2 | 2.0 |
*Disease Models, Animal | 2 | 0.0 |
Cyclophosphamide/*therapeutic use | 2 | 7.0 |
Cytarabine/*therapeutic use | 2 | 13.0 |
Prednisone/*therapeutic use | 2 | 7.0 |
Vincristine/*therapeutic use | 2 | 25.0 |
Intestine, Small/pathology | 2 | 11.0 |
T-Lymphocytes/*immunology/physiology | 2 | 5.0 |
Complement/immunology | 3 | 3.0 |
Leukemia, Lymphocytic/immunology/pathology/*therapy | 2 | 100.0 |
Lymphocytes/*classification/immunology | 2 | 20.0 |
Immunologic Deficiency Syndromes/immunology | 2 | 11.0 |
Leukemia, Lymphocytic/*pathology | 2 | 10.0 |
Leukemia, Lymphocytic/*immunology/pathology | 2 | 18.0 |
*Immunophenotyping/methods | 2 | 28.0 |
Interferon-alpha/*therapeutic use | 2 | 3.0 |
Cytokines/immunology/metabolism | 2 | 9.0 |
